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ABSTRACT

Stutzman, John R. Ph.D., Purdue University, December 2013. Gas-Phase Covalent and
Non-Covalent Ion/Ion Chemistry of Biological Macromolecules. Major Professor: Scott
McLuckey.
Gas-phase ion/ion chemistry involves the interaction of oppositely charged ions
inside of the mass spectrometer. During this gas-phase chemistry, particle transfer (i.e.,
proton and electron) or synthesis can occur at rapid reaction rates. Particle transfer
represents a mature area of ion/ion chemistry, while selective covalent modification
represents a fairly new area of gas-phase chemistry. Gas-phase covalent chemistry is
based on traditional solution phase organic chemistry.
The work demonstrated in this dissertation greatly involves gas-phase covalent
and non-covalent Schiff base chemistry on peptide and protein ions. The reagent dianion,
4-formyl 1,3-benzene disulfonic acid, has been used to covalently modify unprotonated
primary amines present in peptide and protein ions. In addition, strong non-covalent
interactions have also been observed with arginine-containing peptides ions. Studies of
their dissociation behavior as well as the nature of their interaction (i.e., covalent versus
non-covalent) have been investigated. Application of this Schiff base ion/ion chemistry
has been demonstrated on matrix assisted laser desorption/ionization (MALDI)-derived
peptide ions. Such Schiff base ion/ion chemistry, whether electrospray or MALDIderived, can produce complementary or even an increase in structural information.

xv
Multiple covalent modifications within one ion/ion encounter have been demonstrated on
peptide and protein cations via Schiff base cluster anions.

This dissertation also

highlights the gas-phase transformation of phosphatidylcholine cations into demethylated
phosphatidylcholine anions, which provides an increase in structural information upon
activation.

As a whole, gas-phase covalent and non-covalent ion/ion chemistry

represents a promising new area for identifying and characterizing biological analytes.

1

CHAPTER 1. INTRODUCTION TO BIOLOGICAL MASS SPECTROMETRY AND
ION/ION CHEMISTRY

1.1

Tandem Mass Spectrometry

Tandem mass spectrometry (MS/MS) utilizes multiple stages of ion separation (i.e.,
ion isolation) and identification (i.e., dissociation and detection) in the gas-phase. 1,2,3
This methodology has revolutionized mass spectrometry as an analytical tool since its
inception in the early 1970’s.1 MS/MS is based on the detectable difference in the
mass/charge (m/z) ratio of a precursor ion prior to the final stage of analysis. A
dissociation method or chemical reaction are generally employed to cause a change in the
precursor ion.

In order to achieve detection following multiple stages of MS, the

precursor ion must be stable in the first stage of MS and the product ion must be stable in
the second stage of MS. Such a requirement provides high selectivity and a drastic
reduction of chemical noise as the other ions do not satisfy the conditions for detection.4
The process of tandem MS is analogous to chromatographic separations due to the extra
dimension added to mass spectrometry upon separation of one component from an
ionization spectrum. Instead of separation based on retention behavior, analytes can be
separated on their molecular weight.5
Tandem mass spectrometry can be either performed in time or space. MS/MS in
space involves multiple stages of MS that are physically separated, i.e. coupling two or
more distinct mass analyzers. In space MS/MS has been applied to sectors, time-of-flight
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(TOF), and multiple quadrupole devices.4,5 For instance, the triple-quadrupole MS (QqQ)
has been the standard in tandem MS for the past few decades. The triple quad is
comprised of a mass filter (Q1), an rf-only collision cell (q2), and a mass filter for
product ion mass analysis (Q3). 6 Since commercialization of these platforms, many
operational modes have been developed for high throughput MS analysis: precursor ion
scan, product scan, neutral loss scan, and selected reaction monitoring.5 In all of these
scan-types, fragmentation occurs via beam-type collisional activation in the collision
cell.6 Alternatively, MS/MS in time involves multiple stages of MS (i.e., isolation and
dissociation) sequentially in the sample ion trap. This type of tandem MS is performed in
ion traps (i.e., 2-D and 3-D) and ion cyclotron resonance cells. A significant benefit of
tandem MS in time is the ability to perform MSn experiments, where up to seven or eight
stages have been demonstrated.4,5

1.1.1

Collision Induced Dissociation of Biological Macromolecules

In tandem mass spectrometry, energetic collisions with a neutral target gas are the
most commonly used activation method of biological ions. This process of collisional
activation followed by fragmentation is referred to as collision-induced dissociation
(CID). CID has proven to be extremely useful and effective for the identification and
structural characterization of biological macromolecules. This fact can be attributed to the
ease of implementation, universal applicability, and high CID cross sections. As a result,
tandem MS with CID has emerged as a powerful tool in proteomics and other “omic”
areas as structural information can provide insight on physiological processes. In fact,
gas-phase unimolecular dissociation of proteins and peptides is a continuing area of
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research in hopes to generate algorithms that predict fragmentation behavior as well as to
further fundamental understandings.

There are multiple factors that influence the

dissociation behavior of biological ions. Some of these factors include the activation
time period relative to dissociation or rearrangement, the activation energy deposited, the
distribution of deposited energy, the form of deposited energy (i.e., vibrational versus
electronic), the time scale of instrument observation, and the efficiency of the CID
process.
Ion trap CID is considered a slow heating method (i.e., 10-100 millisecond time
frame), where multiple collisions can occur with considerable time periods between each
collision. Such a time scale allows for isomerization or dissociation during activation.
Typically, 1-100 eV kinetic energy is deposited into the bio-ion in low energy CID
processes such as ion trap CID. Alternatively, fast activation methods (i.e., microsecond
time frame) deposit kilo-election-volt energies with only a few collisions with neutral
bath gas. Generally, high energy/fast activation CID is performed on sector-based and
tandem TOF instruments. 7

1.2

Proteomics

Proteomics can be defined as the study of proteins with a particular interest in
their structure and function.

Identifying proteins and their covalent structures has

become central to the life sciences.8 The primary sequence (i.e., amino acid composition)
of a protein relates to a specific gene, thus providing a link between cell physiology and
genetics. 9 Proteomic analysis can be quite complex and difficult due to the relative size
and diversity of a proteome. In fact, the number of proteins in a proteome greatly
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exceeds the number of genes. This finding can be attributed to alternating splicing of
primary transcripts, the present of sequence polymorphism,8,9 post-translation
modifications (PTMs),8,9,10 and other protein processing mechanisms.8,9
The field of proteomics heavily relies on mass spectrometry and tandem MS as
an analytical tool to analyze and characterize these analytes.11 Mass spectrometry and
tandem mass spectrometry provides a fast and robust platform to determine the mass
information and relative abundance of the analyte ions and their fragment ions.4,5
Initially, MS was restricted to small and thermostable compounds due to the inability to
ionize larger analytes from the solution phase to the gas-phase without extensive
fragmentation. 12 , 13 The advent of soft ionization techniques, electrospray ionization
(ESI) 14 and matrix assisted laser desorption/ionization (MALDI), 15 , 16 afforded the
introduction of gaseous biological macromolecules into the MS. These significant
contributions have fueled new innovations in MS instrumentation as well as biological
applications for proteome characterization.
Two conventional methods of protein identification in MS are bottom-up and topdown proteomics.

Bottom-up proteomics is the most common and widely utilized

approach to characterize proteins. In bottom-up, peptides generated by an enzymatic
digestion of a protein17 are subjected to MS/MS, 18,19 where the precursor masses of the
peptide ions and the subsequent dissociation behavior are compared to a protein database
for identification.20 This process is generally coupled with liquid chromatography and
highly automated. Peptide analytes generally ionize easily via ESI or MALDI and their
fragmentation behavior is quite straightforward18 (i.e., cleavage at the peptide bond
forming b- and y-ions). In addition to these advantages, there are several key drawbacks
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to this methodology. Foremost, enzymatic digestion generates a fraction of the total
theoretical peptides; therefore, only limited primary sequence is observed.21 Potentially,
PTMs like phosphorylation, sulfonation, and glycosylation, can be lost due to the limited
production of peptides. In addition, a single peptide or a group of peptides may not be
unique to a single protein, but shared among multiple proteins. Such a fact will cause
ambiguity with protein assignments.18,21,22 Alternatively, the top-down approach subjects
the intact protein to mass analysis and characterization without recourse to extensive
separation or digestion.23 Mass analysis of gaseous protein ions has been demonstrated
up to 200kDa. 24 In principle, dissociation of an intact protein ion enables the entire
sequence for examination, enabling complete characterization of the protein. Since this
approach allows for intact mass information, redundant identifications by peptide
sequencing strategies can be eliminated by simple identification of isoforms and PTMs.18
Additionally, the masses of intact mass of proteins ion generated by ESI are spread over a
wider mass range than ezymtically derived peptides, thus alleviating complex mixture
analysis.22 Some drawbacks to this method include complex fragmentation behavior and
difficulties generating stable ion signal.22

1.3

Lipidomics

The area of lipidomics pertains to the identification and quantification of lipids
within a biological system as well as their effect on the function or dysfunction on
various physiological pathways.

Lipidomics has emerged as an important area of

research due to new insights on lipid-lipid and lipid-protein interactions as these
biological

macromolecules

have

distinct

biochemical

roles

and

biophysical
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properties. 25 , 26 Traditionally, lipids have been characterized solely on their physical
properties, i.e. solubility in nonpolar solvents, instead of their physiological roles. Recent
publications and investigators have tried to redefine this traditional definition.25
Lipids are quite distinct from the other classes of biological macromolecules, i.e.
proteins and nucleic acids.

Instead of permutations of common monomers, lipids

encompass a wide range of molecular structures. Common lipid classes include fatty
acids, glycerolipids, glycerolphospholipids, sterol lipids, and sphingolipids. Within each
lipid classes, there is high degree of diversity which leads to an extraordinary number of
combinations.27 This diversity does not account for isomeric lipids that differ only by the
double bond position, backbone substitution, and stereochemistry. 28 Due to this high
degree of diversity, lipidomics progressed and developed much more slowly than
proteomics and genomics. As such, MS has become the analytical tool of choice to
address the diverse range of molecular structures due to its speed, selectivity, etc.25 In
lipidomics, two strategies have been employed: targeted lipidomics and global lipidomics.
Target lipidomics focuses on the identification and quantification of a single lipid within
a tissue or cellular extract, while global lipidomics attempts to identify and quantify all of
the lipids in a system.29 Overall, mass spectrometry has advanced the field of lipidomics
greatly over the recent decade.

7
1.4

Gas-Phase Ion/Ion Reactions

Gas-phase ion/ion reactions have emerged as an analytically useful reaction within
the mass spectrometry. 30 These reactions represent a flexible and rapid means to
manipulate and characterize biological macromolecules in the gas-phase. Three classes
of ion/ion reactions currently exist: acid/base reactions, redox reactions, and covalent
bond formation. Acid/base and redox reactions represent areas of detailed investigation,
while the selective covalent bond formation at specific functional groups represents a
relatively new area of ion/ion chemistry. 31 This work in this dissertation extensively
utilizes acid/base and covalent bond formation ion/ion chemistry.

1.4.1

Instrumentation

Ion/ion reactions have been performed in 3-D quadrupole and linear quadrupole
(2-D) ion traps at reduced pressures (millitorre regime).32,33 Linear ion traps have several
distinct advantages over 3-D traps in relation to ion/ion chemistry. These advantages
include the improved dynamic range and the enhanced efficiency of coupling to external
ion sources, detectors, and other mass analyzers.34 Conventional trapping in a 2-D trap
utilizes static potentials (DC) on the containment lenses; however, the static potential will
only be sufficient to axially trap one ion polarity. In order to perform ion/ion reactions
on linear ion traps, an auxiliary alternating current (AC) is superimposed on the
containment lenses of the quadrupole ion trap to afford mutual storage of oppositely
charged ion populations. The 2-D ion traps provide sufficient spatial overlap of both ion
populations, causing these vessels to be well suited for gas-phase ion/ion reactions.33
These ion traps also provide the ability to perform multiple stages of mass spectrometry
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(i.e., ion isolation and activation), which is desirable for characterization, ion
manipulation, and mass analysis.
The instrument control of an ion/ion reaction and bipolar ion introduction is fairly
straightforward. Ions of opposite polarity are sequentially injected into the reaction
quadrupole via alternately pulsed nanoelectrospray (nESI) emiters. During the injection
of one polarity, one component of the population may be isolated or activated prior to the
ion/ion reaction. Once the desired ion population reaches the reaction quadrupole, the
ion population is trapped with static potentials on the containment lenses. Next, the
opposite polarity ion population is injected into the reaction cell, whereby the
supplemental AC is applied to the containment lenses to trap both polarity of ions. The
ions are allowed to react for a predefined period of time, where the product ions are
subjected to further tandem MS and mass analysis.33,34,35

1.4.2

Thermodynamics of Proton Transfer Reactions

The generic energy diagram for a proton transfer ion/ion (see process (1)) reaction
is displayed in Figure 1 (a).36 This energy diagram is analogous to the Brauman diagram.
The entrance channel is dominated by the long range, charge dependent attractive
potential –Z1Z2e2/r. Here, Z1 and Z2 are the nominal charges of the cation and anions, e is
the elementary charger, and r is the distance between the two ions. Once the orbiting pair
is formed, the reactants must overcome ion-dipole and ion-induced dipole (assuming one
product is completely neutralized) to proceed over the exit channel barrier. The enthalpy
of reaction is established by the difference in the proton affinity (PA) of [M+(n-1)H](n1)H+

and [A-H]-, as seen in process (2).
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[M+nH]nH+ + [A-H]- → [M+(n-1)H](n-1)H+ + A

(1)

ΔHrnx = PA([A-H]-) – PA([M+(n-1)H](n-1)H+)

(2)

The significant disparity in energy between the highest proton affinities of neutral bases
and the lowest proton affinities of anions generates a highly exothermic process; and
therefore, deprotonation of the strongest of gaseous bases will occur in the presence of
singly charged anions.

Ion/ion reactions are generally exothermic by at least 100

kcal/mol for any charge n.31 As the degree of excess protonation increases (i.e. increase
in n), the reaction exothermicities increase due to the decreasing proton affinity of the
cations. In fact, from a thermodynamic standpoint, a reaction should always occur
between oppositely charge ions.
In comparison, the energy diagram of gas-phase proton transfer ion/molecule
reactions is diplayed in Figure 1 (b). The reaction process can be seen in process (3).36
The entrance channel of an ion/molecule reactions is dominated by shorter-range
polarization forces, which is analogous to the exit channel of the ion/ion reactions. As
for the exit channel of an ion/molecule reaction (same charged product ions), the
repulsive +Z1Z2e2/r potential is dominant and creates a coulomb barrier. Overall, the
energy surface can be described by the reaction enthalpy of ion/molecule reactions. The
reaction enthalpy is determined by the difference of proton affinities of B and [M+nH]nH+,
as seen in process (4).
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[M+nH]nH+ B → [M+(n-1)H](n-1)H+ + [B+H]+

(3)

ΔHrnx = PA([B]-) – PA([M+(n-1)H](n-1)H+)

(4)

Since the proton affinity of a neutral base (B) is significantly lower than [A-H]-, proton
transfer ion/molecule reactions are always less exothermic than the ion/ion reactions and
are likely to be endoergic processes.

1.4.3

Kinetics

When there is a vast excess of reagent ions, pseudo first order kinetics are
achieved for forming a bound orbiting pair of oppositely charged ions. Under these
conditions, the rate of analyte ion depletion has shown a charge square dependence,
which is consistent with the r-1 attractive potential for the formation of a bound orbiting
pair (vide supra).36 The rate constant for the formation of a stable orbit is shown in
equation (1):
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where εo is the vacuum permittivity, µ is the reduced mass of the two reactants, and v is
the relative velocity of the bipolar ions. Stable orbits can be achieved at relatively long
distances due to the long-range attractive potential. At such long distance, chemistry
cannot occur between the two ion populations. Bound orbits can either have high or low
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eccentricity. High eccentricities will ultimately reach a distance during the orbit where a
reaction will occur.

At low eccentricities, a mechanism to bring the orbiting pair

sufficiently close must occur in order for a reaction to proceed. Two mechanisms can
account for diminishing orbiting distances: a third body interaction and the tidal effect. A
third body interaction with the orbiting pair can either destroy or reduce the relative
velocities of the orbiting pair. By reducing the relative velocities of the orbiting pair,
smaller orbital distances are achieved and reaction will proceed. Bath gas (i.e. helium,
nitrogen) in the reaction quadrupole at sufficient number densities will act as a third
body.31,36 The tidal effect, however, is a more plausible mechanism for macroions (i.e.,
peptides, proteins). Macroions have significant internal structure that can be affected by
the changing electric field associated with the bound orbit. 37,38 These rapid changes
cause translational energy to internalize, thus reducing the relative velocities.31

1.4.4

Proton Transfer Ion/Ion Reactions

Single proton transfer reactions have been routinely performed in electrodynamic
traps.34, 39 The charge state of reactant ions can range drastically: multiply charged
cations with singly charged anions, multiply charged anions with singly charged cations,
and both multiply charged anions and cations. Single proton transfer can occur via a
proton hopping mechanism or a long-lived intermediate complex. The proton hopping
mechanism occurs when reactant ions fly past one another in their bound orbit and the
energy is sufficient for proton transfer (vide supra). Complex formation, or long-lived
intermediate complex, involves a sticky collision, where the two reactants come into
intimate contact. During the lifetime of the complex, single or even multiple proton
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transfers can occur. Collisional activation of long-lived complexes, comprised of a
multiply charged cation and monoanion, generates charged reduced product ions (e.g., n1), demonstrating the ability to perform proton transfer reactions through a long-lived
complex.40
Since its inception, there have been many applications for proton transfer
reactions in the gas-phase. These reactions have been demonstrated on mixtures of
biomolecular ions (i.e., nucleic acid and proteins). 41,42,43,44 Reducing the mixture of
multiply charged ions to predominately singly charged ions, regardless of the initial
charge, provides multiple benefits: simplifying the mass spectrum and removal of
overlapping charge state distributions, etc.31 In addition to reducing the charge state of
ESI-generated mixtures, proton transfer reactions can be applied to collisional activation
product ions.

Collisional activation of multiply charged ions can lead to complex

mixtures of different masses and charges. 45,46 ,47 ,48 ,49 , 50 ,51 ,52 , 53 ,54 The proton transfer
reactions can simplify the MS/MS data by converting all the product ions to mainly
singly charged ions. Application of this chemistry to MS/MS product spectra allows for
confident assignment, less complexity, and higher database confidence scores.

In

addition, the extent of consecutive proton transfer reactions can be controlled by a
technique deemed ion parking.55 Using selective ion acceleration techniques (i.e., low
amplitude resonant excitation on desired m/z), inhibition of consecutive ion/ion reactions
can be selected at a desired analyte charge state.
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1.4.5

Charge Inversion Ion/Ion Reactions

The ion/ion chemistry discussed to this point has exclusively dealt with single
proton transfer or consecutive ion/ion reactions. A unique ion/ion reaction involves the
conversion of analyte ions from one polarity into the opposite polarity. 56,57,58 Charge
inversion can only be achieved by forming a long-lived intermediate complex, where
multiple protons can be transferred within the complex prior to dissociation, as seen in
process (5).40 In order to perform charge inversion, the number of transferred protons to
the analyte ion must exceed the number of charges that neutralize the analyte. Achieving
consecutive ion/ion reactions that invert the polarity of the analyte are highly unlikely
due to neutralization and the resulting low number densities of the neutral and reactant
ions.56,57

In addition to multiple proton transfers, adduct formation with multi-charged

and highly polarizable ions can undergo charge inversion.56 Here, the charge of the
adduct exceeds that of the analyte ion by at least one and the long-lived complex does not
dissociated in the time frame of the experiment, as seen in process (6).

[M+H]H+ + [R-nH]n- → [M-H]- + [R-(n+2)H](n+2)-

(5)

[M+H]H+ + [R-2H]2- → [M+R-H]-

(6)

Charge inversion ion/ion chemistry has owned a wide range of applications.
59,60,61,62

Simply changing the polarity of the analyte ion can provide complementary or

even additional sequence information. This chemistry is utilized in situations where the
most abundant ionization mode is not necessarily the best polarity for activation. Charge

14
inversion has been utilized to concentrate multiply cations types (i.e., [M+Na]+, [MH+2Na]+, [M-2H+3Na]+) into a singly analyte anion type (i.e., [M-H]-)60 as well as the
reduction of chemical noise in a complex mixture.61 Charge inversion has also been
utilized to increase the charge, or “charge up”, analyte anions into multiply protonated
analyte ions.62,63

1.4.6

Covalent Ion/Ion Chemistry

The chemistries discussed above have been restricted to particle transfer and noncovalent interactions.

A new area of ion/ion chemistry that has emerged recently

involves forming covalent bonds at specific functional groups.64,65,66,67,68 Much of this
gas-phase chemistry has been largely based on classic solution phase organic chemistry.
Solution phase derivatization in mass spectrometry has been used to facilitate analyte
ionization, 69 quantification, 70 , 71 and characterization. 72 , 73 Mainly, gas-phase covalent
chemistry has been incorporated into typical MSn workflows to provide characterization
in various biological macromolecules (i.e., proteins and peptides).

Gas-phase

derivatization provides multiple inherent benefits: speed (100s of milliseconds), quick
comparison between modified and unmodified ions, high degree of control over reactants
via mass selection, ability to control the number of modifications, avoidance of complex
reaction mixtures, etc.31
In order to perform a successful covalent modification in the gas-phase, certain
characteristics of the reagent must be present. A reagent ion must contain at least one
polarizable (“sticky”) group to generate strong electrostatic interactions between the
reactant ions as well as a reactive functionality, i.e. a bifunctional reagent ion. The sticky
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group serves to anchor the reagent to the analyte ion so as to allow sufficient time for the
reactive functionality to undergo a chemical reaction. The long lifetime of the complex
generates high reaction efficiencies due to multiple interactions between the reactants and
the effectively high concentration of reagent per analyte.

Sulfonate and quaternary

amines have been demonstrated to be excellent functionalites for promoting strong noncovalent interactions. Sulfonates, which are anionic in nature, generate strong
electrostatic interactions with biological cations (i.e., lipids, nucleic acids, proteins, and
peptides).64

Alternatively, quaternary amines, which contain fixed positive charges,

generate strong electrostatic interactions with biological anions.65 Site specific covalent
modification of unprotonated amines in the gas-phase has been demonstrated via Schiff
base and N-hydroxysuccunimide (NHS) ester chemistry.64,65,67 In addition to primary
amine modification, covalent modification has been demonstrated on carboxylic acid
functionalities with carbodiimide reagents.68 Both the carbodiimide and NHS chemistry
generate amide linkages, while the Schiff base chemistry generates imine bonds. For the
most part, gas-phase covalent chemistry has been used to covalently tag,64,65 increase
structural characterization,67 map three dimensional structure,74 and discover unique or
rare chemistry.66

1.4.6.1 Schiff Base Covalent Chemistry
Covalent ion/ion chemistry involving schiff base reagents will be discussed in
greater detail than the NHS or carbodiimide chemistry due to the relevance with this
dissertation. Schiff base formation involving either the N-terminus or the ϵ-NH2 group of
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lysine residues has been demonstrated by reacting peptide cations with either singly or
doubly deprotonated 4-formyl-1,3-benzenedisulfonic acid (FBDSA). A sulfonic acid
group in the reagent anion can interact strongly with a protonated site on the peptide
resulting in a long-lived complex (Scheme 1). Upon collisional activation of the complex,
the aldehyde group can undergo nucleophilic attack by an available unprotonated primary
amine resulting in loss of water and formation of a Schiff base. Water loss from the
complex is a signature of Schiff base formation, although water loss is a common process
from peptide ions.
Singly deprotonated FBDSA is useful for modifying multiply-protonated peptides,
as shown in process (7).64 Note that the diamond symbol (♦) corresponds to the addition
of FBDSA to M with loss of a water molecule. Doubly deprotonated FBDSA can be
used to modify singly protonated peptides via charge inversion ion/ion chemistry.67 In
the case of singly protonated peptides, reaction with doubly deprotonated FBDSA results
in the conversion of the peptide cation to an anionic product, as indicated in process (8).

[M+nH]n+ + [FBDSA-H]- → [M+FBDSA+(n-1)H](n-1)+ → [M+♦+(n-1)H](n-1)+ + H2O(7)

[M+H]+ + [FBDSA-2H]2- → [M+FBDSA-H]- → [M+♦]- + H2O

(8)
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1.5

Future Insights of Ion/Ion Chemistry

Ion/ion reactions represent a flexible methodology to manipulate gaseous
biological macromolecules. With the recent discovery of selective covalent chemistry, a
promising new area of gas-phase reactivity has emerged. Potential areas of impact
include primary sequencing, highly selective cleavages, selective modification of new
biologically relevant functionalities, higher order structure analysis, etc. While many of
the current reagent ions are bifunctional (i.e. reactive and sticky group), there is a need
for trifunctional reagents. In addition to a sticky group to facilitate a long-lived complex
and a reactive group to covalently bind the reagent to the analyte, a third functionality is
needed to perform new chemistries that may not be accessed without covalent attachment
(i.e., disruption of the long-lived complex prior to reaction). Other promising areas
include laser activation/dissociation in conjunction with ion/ion chemistry as well as
metal coordination chemistry.
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Figure 1.1: Generic energy diagrams for (a) an proton transfer ion/ion reaction (b) proton
transfer ion/molecule reaction
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Scheme 1: Summary of the charge inversion process involving covalent modification of
unprotonated primary amines via gas-phase ion/ion reactions with FBDSA dianions.
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CHAPTER 2. DISSOCIATION BEHAVIOR OF TRYPTIC AND
INTRAMOLECULAR DISULFIDE-LINKED PEPTIDE IONS MODIFIED IN
THE GAS-PHASE VIA ION/ION REACTIONS

2.1

Introduction

Primary structure characterization by mass spectrometry is generally dependent
upon fragmentation of ions derived from the molecule of interest. The two main options
for maximizing the structural information of interest are selection of ion-type (e.g.,
protonated molecule versus radical cation versus deprotonated molecule, etc.) and ion
activation conditions.1 The ion-type is usually determined by the means for ionization. It
is also common to subject analyte species, such as peptides or proteins, to a derivatization
reaction in solution to facilitate ionization,2 quantification,3 or structural characterization4
via mass spectrometry or tandem mass spectrometry. Alteration of the ion-type can also
take place in the gas phase via ion/electron,5 ion/molecule,6 or ion/ion reactions.7 Most
gas phase reactions have involved the gain or loss of protons or electrons by the analyte
ions. Examples of selective covalent modification of polypeptide ions in the gas-phase
are restricted to ion-molecule8 and ion/ion reactions and are still rare. However, several
recent findings suggest that the selective modification of primary amines in peptide ions
via ion/ion chemistry is straightforward via either Schiff base formation9 using aldehyde
containing reagents or via amide bond formation 10 using N-hydroxysuccinimide ester
containing reagents. The ability to form covalent bonds selectively in the gas-phase
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opens up new possibilities for probing the structures of gaseous polypeptides.

For

example, the cross-linking of peptide ions in the gas-phase has recently been
demonstrated using bi-functional N-hydroxysuccimide ester reagent ions.11
Schiff base formation involving either the N-terminus or the ϵ-NH2 group of
lysine residues has been effected by reacting peptide cations with either singly or doubly
deprotonated 4-formyl-1,3-benzenedisulfonic acid (FBDSA). A sulfonic acid group in
the reagent anion can interact strongly with a protonated site on the peptide resulting in a
long-lived complex. Upon collisional activation of the complex, the aldehyde group can
undergo nucleophilic attack by an available unprotonated primary amine resulting in loss
of water and formation of a Schiff base. Water loss from the complex is therefore
consistent with Schiff base formation, although water loss is a common process from
peptide ions. Strong electrostatic interactions between the reagent anion and the peptide
cation can occur, particularly between the sulfonate group and protonated arginine.
Hence, either covalent or non-covalent modification of the peptide may alter the
fragmentation behavior of a peptide ion. The identities of the fragmentation products
arising from further activation of the water loss product to give cleavages along the
peptide backbone can provide clues regarding the nature of the modification. Loss of
intact FBDSA, for example, from the water loss product is a clear indication of an
electrostatic interaction for those ions that undergo this loss.
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Singly deprotonated FBDSA is useful for modifying multiply-protonated
peptides9, as shown in process (1):

[M+nH]n+ + [FBDSA-H]- → [M+FBDSA+(n-1)H](n-1)+→ [M+♦+(n-1)H](n-1)+ + H2O

(1)

Note that the diamond symbol (♦) corresponds to the addition of FBDSA to M minus a
water molecule. Doubly deprotonated FBDSA can be used to modify either singly
protonated peptides or peptides with three or more excess charges in a single step. In the
case of singly protonated peptides, reaction with doubly deprotonated FBDSA results in
the conversion of the peptide cation to an anionic product, as indicated in process (2):12

[M+H]+ + [FBDSA-2H]2- → [M+FBDSA-H]- → [M+♦]- + H2O

(2)

Doubly protonated peptides can also undergo charge inversion in reactions with FBDSA
di-anions but this entails two consecutive ion/ion reactions with the first involving single
proton transfer (process (3)) to yield the singly protonated peptide, which can then
undergo process (2):

[M+2H]2+ + [FBDSA-2H]2- → [M+H]+ + [FBDSA-H]-

(3)

Single proton transfer, as represented by process (3), competes with long-lived complex
formation, which constitutes the first step of processes (1) and (2).13 Complex formation
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is the dominant process for the species relevant to this work but single proton transfer
typically occurs as a competitive process.
All work to date using ion/ion reactions involving FBDSA anions with peptide
cations has indicated that the modified products upon collisional activation often yield
sequence information that is complementary to that derived from unmodified ions.9,12
However, the work has been restricted to a limited number of model peptide ions. In this
work, we have extended the range of observations to include peptides with an
intramolecular disulfide linkage as well as ions derived from tryptic digestion of a protein.
Tryptic peptides are of interest because of their relevance to bottom-up protein
identification. 14

Peptides with intra-molecular disulfide linkages often present a

challenge for deriving sequence information, particularly for protonated peptides, due to
the fact that the disulfide linkage must be cleaved along with a backbone bond.15,16 In
this work, somatostatin-14 and oxytocin, two peptide hormones, were chosen as model
cyclic peptides.

2.2

Experimental Section

2.2.1

Materials

Methanol, glacial acetic acid, and ammonium hydroxide were purchased from
Mallinckrodt (Phillipsburg, NJ).

Ubiquitin from bovine erythrocytes, TPCK treated

trypsin from bovine pancreas, somatostatin-14, 4-formyl-1,3-benzenedisulfonic acid, tris
(2-carboxyethyl) phosphine hydrochloride, and ammonium bicarbonate were purchased
from Sigma-Aldrich (St. Louis, MO).

Peptides MQIFVK, TITLEVEPSDTIENVK,
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EGIPPDQQR, LIFAGK, TLSDYNIQK, and ESTLHLVLR were generated from the
digestion of ubiquitin by trypsin. Oxytocin was obtained from Bachem Bioscience Inc.
(Torrance, CA). Peptide analytes were prepared in ~100 µM aqueous solution prior to
positive nanoelectrospray ionization (nESI).

The anion reagent was prepared at a

concentration of 3.5 mM in solution of 49.5/49.5/1 (v/v/v) water/methanol/ammonium
hydroxide for negative nESI.

2.2.2

Tryptic Digest

The procedure for the tryptic digestion of ubiquitin has been described
previously. 17 Separation of the tryptic peptides was performed using a reverse-phase
HPLC (Agilent 1100, Palo Alto, CA) equipped with an Aquapore RP-300 (7µm pore size,
100 x 4.6 mm i.d.) column (Perkin-elmer, Wellesley, MA). The gradient for the HPLC
separation has been described previously.17 Following separation, collected fractions
were lyophilized and dissolved in 250 µL of water.

2.2.3

Disulfide Reduction

The procedure for disulfide reduction has been described previously.18 Reduced
cyclic peptides were filtered through a disposable PD-10 desalting column (GE
Healthcare) using a 1% acetic acid solution. Collected fractions were lyophilized and
dissolved in 250 µL of water.
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2.2.4

Mass Spectrometry

Experiments were performed on QqQ tandem mass spectrometers (QTRAP 2000
and QTRAP 4000, AB Sciex, Concord, ON, Canada), which have been modified for
ion/ion reactions.19 The QTRAP 4000 was used in cases in which the Schiff base product
ions were of m/z greater than 1700 due to its higher mass range. Alternately pulsed ESI
emitters allowed for sequential ion injection into the q2 reaction cell.20,21 First, doubly or
singly deprotonated FBDSA was accumulated in the q2 reaction cell. Next, the peptide
cations were generated and transferred to the q2 cell to undergo mutual storage with the
FBDSA anions for 500-1200 milliseconds. The product ions were then transferred to the
Q3 ion trap for subsequent mass analysis via mass-selective axial ejection (MSAE)22 or
for further interrogation via MSn.

2.3

Results and Discussion

2.3.1

Tryptic Peptides

Ubiquitin was subjected to digestion with trypsin and cations derived from the
following peptides were observed in the positive nESI mass spectrum: MQIFVK,
LIFAGK, TITLEVEPSDTIENVK, EGIPPDQQR, TLSDYNIQK, and ESTLHLVLR.
Cations of each of these peptides were subjected to ion/ion reactions with anions derived
from FBDSA and the results are provided below and in Supplementary Information. In
all cases, comparisons were made of the CID behavior of the unmodified [M-H]- peptide
as well as that of the singly or doubly protonated species.
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The ion trap CID product ion spectrum of the modified TLSDYNIQK anion is
compared to those of the singly deprotonated and doubly protonated forms of the peptide
in Figure 1. In this case, cations of TLSDYNIQK were reacted with [FBDSA-2H]2- to
yield the negatively charged [TLSDYNIQK+FBDSA-H]- complex. Ion trap collisional
activation of the complex gave rise to a highly abundant water loss product, which is
indicated as [M+♦]- in Figure 1(a). The diamond symbol (♦) associated with some
products indicates a fragment that is consistent with the indicated product with the
expected mass shift associated with the covalent modification. We note, however, that
the labeled fragments can also, in principle, arise from non-covalent FBDSA adduction
with water loss arising elsewhere in the peptide ion. In this particular case, no clear
evidence for electrostatic binding, such as the appearance of [FBDSA-H]- or the
attachment of FBDSA to a product ion (see below) is apparent. The most abundant
products are consistent with modified y-type and b-type ions, using the nomenclature that
is adapted23 from the protonated peptide literature,24 which would correspond to α-ions
and β-ions, respectively, in the nomenclature employed by Bowie.25 When compared to
the unmodified anion (i.e., the [M-H]- ion), the CID of the modified peptide in this case
generates more sequence information (compare Figures 1(a) and 1(b)). Figure 1(c)
shows the CID product ion spectrum of doubly protonated TLSDYNIQK, as this is the
most abundant cation in the nESI mass spectrum. The modified peptide and the
unmodified peptide cation of TLSDYNIQK produce similar sequence information
(Figures 1(a) and 1(c)). Both spectra reflect cleavages of the same peptide bonds,
although the relative contributions differ markedly. For example, the complementary
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y7/b2 pair dominates the cation spectrum whereas less selectivity in cleavage among
amide bonds is apparent in the CID of the modified anion.
The results of TLSDYNIQK are illustrative for tryptic peptides with a C-terminal
lysine residue. The results for ions derived from MQIFVK (Figure 2), LIFAGK (Figure
3), and TITLEVEPSDTIENVK (Figure 4) are provided as Supplementary Information.
In all three cases, the major fragmentation products from the [M+♦]- ions correspond to
y♦- or b♦-type ions. The CID product ion spectra of the [M-H]- ions, on the other hand,
provide fewer sequence-informative fragment ions.

The results reported here are

consistent with previous work involving condensed-phase covalent derivatization of the
C-terminus of peptides with 4-aminonaphthalenesulphonic acid.26 The resulting anions
showed abundant modified y-type ions, the origin of which was attributed to a chargeremote mechanism.27,28 The sulfonate anionic site is highly stable and is expected to
inhibit intramolecular proton transfer relative to a carboxylate site, thereby reducing the
contributions from at least some charge-mediated reactions.
Fragmentation spectra of the modified tryptic peptides with a C-terminal arginine
residue shared commonalities with those of the C-terminal lysine peptides but also
showed some unique products. As an example, the CID product ion spectra for ions
derived from EGIPPDQQR are compared in Figure 2. In the spectrum of the [M+♦]- ion,
both b♦- and y♦-ions are observed (Figure 5(a)), which suggests that the precursor ion
population is comprised of a mixture of species with the attachment at either end of the
peptide. However, the N-terminus is the only site with an available primary amine for
Schiff base formation. The y♦-ions are interpreted to arise from precursor ions with
strong electrostatic attachment of a sulfonate group to the guanidinium side-chain of the
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C-terminal arginine residue, such interactions are known to be strong in the condensed
phase 29 , 30 or via formation of a negatively charged proton-bound dimer with the Cterminus. Ion/ion charge inversion studies have shown that the C-terminus can play an
important role in adduct formation.13,31 The water loss resulting from activation of the
[EGIPPDQQR+FBDSA-H]- complex presumably can arise from several sites on the
peptide (e.g., the Glu and Asp residues). The appearance of abundant [y+FBDSA]products in Figure 2(a) is consistent with this interpretation, as the site from which water
is lost is not expected to be dependent upon the site of electrostatic attachment. On the
other hand, the water lost upon Schiff base formation must come from the aldehyde
group of FBDSA. If all peptide ions were to undergo Schiff base formation, no products
with an FBDSA adduct should appear.
Ion trap CID spectra of the [M-H]- and [M+2H]2+ ions of EGIPPDQQR are
shown in Figures 5(b) and 5(c), respectively. The [M-H]- ion provides relatively few
sequence-related product ions, the most prominent of which is the c5-ion, presumably
arising from the previously noted cleavage associated with the aspartic acid side-chain.25
The doubly protonated species generates a series of complementary b- and y-type ions
with cleavage N-terminal to the proline at the fourth residue accounting for a large
fraction of the observed fragmentation. Clearly, each precursor ion reflected in Figure 2
gives distinct fragmentation pattern. It is particularly noteworthy that the apparent noncovalent attachment of FBDSA can affect cleavage of the peptide backbone, rather than
lose FBDSA, at least for the arginine-containing peptides. A similar set of comparisons
for ESTLHLVLR is shown in Figure 6.
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2.3.2

Intramolecular Disulfide-Linked Peptides

Cations of two peptides with an intramolecular disulfide linkage, somatostatin-14
and oxytocin, were subjected to ion/ion reactions with anions of FBDSA to explore the
effect of modification on fragmentation of the cyclic portions of the peptide ions.
Polypeptide ions with intramolecular disulfide linkages, particularly protonated forms,
often show little evidence for cleavage within the peptide loop defined by the disulfide
bridge.15

For this reason, the peptides are often reduced prior to tandem mass

spectrometry. 32 However, gas-phase means for the selective cleavage of disulfide
linkages have also been explored, such as the CID of deprotonated species, 33,34 CID of
alkali or alkaline earth cationized ions,35 CID of coinage metal cationized ions,15,36,37
photodissociation,38 electron induced dissociation,39 electron capture dissociation,40 and
electron transfer dissociation.15

Some approaches rely on altering the ionization

conditions while ECD/ETD require the reactant polypeptide to be multiply-charged. The
use of [FBDSA-2H]2- allows for the modification of singly-protonated species.
Figure 7 compares the ion trap CID product ion spectra of the modified form of
somatostatin-14 (i.e., the [M+♦]- species) (Figure 3(a)) with those of the [M-H]- and
[M+H]+ ions (Figures 7(b) and 7(c), respectively). Ion trap CID of the [M+H]+ species
yields essentially no sequence information. As previously reported in the CID of
deprotonated somatostatin,15 the z12-ion and an associated loss of H2S2 dominate the
product ion spectrum (Figure 7(b)). The formation of the z12-ion is a two-step process
that begins with cleavage of the disulfide linkage at the CH2-S bond of Cys3. Some
internal fragments that contain neither the N-terminus nor the C-terminus are also noted,
although much of the low level signal is not readily assigned.15 CID of the modified
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somatostatin ions produces a major loss of FBDSA, which suggests that a significant
fraction of the precursor ions are comprised of a non-covalently bound FBDSA.
However, a series of bn♦+32 ions, where n=3-9, is noted. This series of ions is consistent
with Schiff base formation N-terminal to the backbone cleavage (e.g., the b3♦+32 and
b4♦+32 ions suggest Schiff base formation at the N-terminus while the b9+32 can be
modified at the N-terminus, at Lys4, or at Lys9) as well as cleavage of the CH2-S bond of
Cys14. Ion trap CID of disulfide linked peptide anions have shown cleavage at all three
bonds along the disulfide linkage30 (i.e., at the S-S bond or at either of the CH2-S bonds
of R-CH2-S-S-CH2-R). Evidence for a few bn♦-ions that follow cleavage either at the SS bond or at the CH2-S bond of Cys3 was noted but the abundances were very low
relative to the bn♦+32 ions.
The presence of the disulfide linkage in somtatostatin has a profound effect on the
ion trap CID of all three ion types, as reflected in the respective CID spectra shown in
Figure 8. Modification of reduced somatostatin via reaction with FBDSA dianions leads
to a spectrum rich in sequence-related ions (Figure 4(a)) that is comprised primarily of
b♦- and y♦-type ions. As there is no need to break a disulfide linkage in order to observe
cleavage products between the cysteine residues, no product ions with either missing or
additional sulfur atoms are observed. As expected, the ion trap CID spectrum of the
reduced [M-H]- ion shows no evidence for a z12-ion, as this ion is generated via a
sequential fragmentation that begins with cleavage of the Cys3 CH2-S bond (see Figure
8(b)). Rather, the spectrum is dominated by losses of small neutral molecules, such as
H2S, and one major product from an apparent backbone cleavage that also involved small
molecules losses (i.e., the y12-H2S-NH3 ion). Ion trap CID of the protonated peptide
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(Figure 8(c)) provides a similar range of backbone cleavages to that observed from the
modified anion, although the relative abundances are markedly different. There is a
small degree of complementarity associated with the data of Figures 8(a) and 4(c),
however, as the modified anion shows unique evidence for cleavage of the Cys3-Lys4
amide bond, while the protonated molecule shows unique evidence for cleavage of the
Thr10-Phe11 amide bond.
Oxytocin represents another peptide hormone with a cyclic portion defined by a
disulfide linkage, in this case between Cys1 and Cys6. Figure 5 provides the ion trap CID
product ion spectra from the modified anion (i.e., the [M+♦]- species, Figure 9(a)), the
deprotonated molecule (Figure 9(b)), and the protonated molecule (Figure 9(c)). Similar
to the case for somatostatin, CID of the [M+H]+ and [M-H]- ions of oxytocin produces
limited sequence information.

The unmodified peptide anion and cation produce

products from cleavages between two and three of eight interresidue linkages,
respectively. Activation of the [M-H]- ion produces a few prominent c-ions, which are
commonly observed in CID of deprotonated peptides with an asparagine residue.25
Dissociation of the protonated molecule shows a dominant N-terminal proline cleavage
that falls outside of the loop defined by the disulfide linkage. A cleavage at the same
amide bond is also highly abundant for the modified anion.

Both the protonated

molecule and the modified anion show evidence for cleavage of the disulfide bond in
oxytocin by virtue of the appearance of b- or y-type ions from within the loop defined by
the disulfide bond. Ions that contain both sulfur atoms or no sulfur atoms are clear
indicators of cleavages of the disulfide linkage at CH2-S bonds. Unlike the somatostatin
case, no clear preference for cleavage of either of the two CH2-S bonds is noted for the
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oxytocin ions. The [M+♦]- ions show evidence for cleavages of five of the eight amide
linkages, which yields primary structure information that largely overlaps with that
derived from the protonated molecule. Taken together, the [M+H]+ and [M+♦]- ions
show cleavages at six of eight interresidue linkages. For comparison, the ion trap CID
product ion spectra of the reduced forms of the three ion types are shown in Figure 6.
Fragmentation of the [M-H]- ion (Figure 10(b)) proceeds largely through loss of one or
two molecules of H2S. The [M+H]+ (Figure 10(a)) and [M+♦]- (Figure 10(c)) ions of the
reduced form of oxytocin show evidence for cleavages at six and five interresidue
linkages, respectively. However, the spectrum of the [M+H]+ ion tends to show more
extensive losses of small molecules, such as water and ammonia, than does the [M+♦]ion.

2.4

Conclusions

Doubly deprotonated 4-formyl-1,3-benzenedisulfonic acid reacts with protonated
peptides largely via complex formation. Schiff base formation involving a primary
amine of the peptide and the aldehyde group of the reagent anion can occur in
conjunction with dehydration of the complex. However, water loss that is unrelated to
the reagent can also occur. An electrostatic (or dipole/dipole) interaction between a
sulfonate of the reagent anion and a protonated site on the peptide can be sufficiently
strong that covalent bond cleavages can compete with simple detachment of the reagent.
This work provides evidence for Schiff base formation associated with many of the
ion/ion reactions studied, while, in some cases, the formation of complexes with a strong
electrostatic interaction without Schiff base formation is indicated as well. This work
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suggests that Schiff base formation can generally be expected for tryptic peptides and is
also demonstrated for the peptide hormones somatostatin-14 and oxytocin, which both
contain an intramolecular disulfide linkage. In all cases, the modified anions (i.e., those
that undergo Schiff base formation as well as those that undergo non-covalent anion
attachment) show fragmentation behavior that is distinct from either protonated or
deprotonated forms of the peptide.

Significantly more structural information, in

particular, was derived from the modified anions than from the deprotonated species.
The highly stable sulfonate group is expected to inhibit intramolecular proton transfer,
which likely accounts for the markedly different fragmentation behavior of the modified
anions relative to the deprotonated species. The structural information available from the
dissociation of protonated forms of the various peptides overlapped with that from the
modified anions but some complementarity was noted in most cases. Modification of
peptide ions in the gas-phase via ion/ion reactions is an attractive means for increasing
structural information from dissociation because it does not require chemical
modification in solution. Schiff base formation and strong electrostatic binding are two
possible means for making modifications. Future work will be devoted to understanding
when these phenomena compete, which may point to novel reagents that react
exclusively by one means or the other.

Reprinted (adapted) with permission from Stutzman, J. R.; Hassel, K. M.; McLuckey, S.
A. Int. J. Mass Spectrom. 2012, 312, 195-200. Copyright (2012) International Journal of
Mass Spectrometry.
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derived from M = CYIQNCPLG-NH2 (oxytocin)
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CHAPTER 3. COVALENT AND NON-COVALENT BINDING IN THE ION/ION
CHARGE INVERSION OF PEPTIDE CATIONS WITH BENZENE-DISULFONIC
ACID ANIONS INTRODUCTION

3.1

Introduction

Tandem mass spectrometry has become the method of choice in generating
sequence information from peptides and proteins. 1 , 2 , 3 The major considerations for
structural characterization via tandem mass spectrometry are ion-type and dissociation
method.[4] Typically, the ion-type is determined by the ionization method;5 however,
manipulation of the ion-type in the gas-phase can be achieved via ion/electron, 6
ion/molecule, 7 , 8 and ion/ion reactions. 9 , 10 Gas-phase ion/ion reactions allow for the
decoupling of the ion-type from the ionization method by enabling the facile
transformation of one ion-type into another within the mass spectrometer. One class of
ion/ion reactions is charge inversion, where the ion of interest is produced in one polarity
and then transformed to the opposite polarity.11,12,13 There have been several approaches
to charge inversion, which include multiple ion transfer, 14 , 15 electrostatic adduct
formation,13,16 and covalent adduct formation.17,18 Charge inversion of a peptide cation
by selective modification of a primary amine has been demonstrated via Schiff base
formation using an aldehyde containing reagent.17,18 Charge inversion via electrostatic
adduct formation has also been demonstrated on peptides using sulfonate-containing
dianions, which display a propensity to form relatively stable long-lived complexes.13
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The nature of the analyte ion transformation that takes place in an ion/ion reaction
is highly dependent upon the chemical characteristics of both the analyte and reagent
ions.5 It has recently been demonstrated that selective covalent bond formation can take
place in a gas-phase ion/ion reaction via Schiff base formation 19 and via amide bond
formation using N-hydroxysuccinimide ester-based reagents. 20 Thus far, all ion/ion
reactions that have resulted in covalent bond formation have involved multi-functional
reagents. That is, the reagents have one or more groups that give rise to a strong
electrostatic interaction to facilitate the formation of a relatively long-lived complex as
well as one or more reactive groups. For example, Schiff base formation involving
primary amines in peptides has been demonstrated using anions derived from 4-formyl1,3-benzenedisulfonic acid (FBDSA) as reagents. A charged sulfonate group in the
reagent anion strongly interacts with a protonated site on the peptide, thereby facilitating
the formation of a long-lived complex.

Schiff base formation within the complex

involves the reaction of an uncharged primary amine (e.g., the N-terminus or ϵ-NH2 side
chain of lysine) with the aldehyde functionality of singly or doubly-deprotonated FBDSA.
Upon collisional activation, nucleophilic attack on the carbonyl carbon of the aldehyde
by an unprotonated primary amine leads to imine formation and loss of water. In the case
of a singly protonated peptide in reaction with doubly deprotonated FBDSA, the process
results in charge inversion of the peptide cation via covalent attachment (i.e., Schiff base
formation), as indicated in process (1):
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[M+H]+ + [FBDSA-2H]2- → [M+FBDSA-H]- → [M+♦]- + H2O

(1)

The diamond symbol (♦) represents the addition of FBDSA to the peptide with a loss of a
water molecule. When the diamond symbol is present with fragment ions, this represents
the mass shift associated with a covalent modification.
The original paper describing Schiff base formation upon charge inversion
involving a protonated peptide and doubly-deprotonated FBDSA showed fragmentation
of the [M+♦]- ion that gave a preponderance of evidence for Schiff base formation, with
one exception. A y7♦-ion, along with many abundant b♦-ions, was noted for the [M+♦]species generated by charge inversion of protonated angiotensin II (DRVYIHPF).17 The
y7-ion is, by far, the dominant product ion in the ion trap CID of the [M-H]- ion, while no
b-type ions are observed, but this fragment contains no primary amine groups that might
be expected to undergo covalent modification. This exceptional case was speculated to
result from a sub-population of ions that undergo strong electrostatic binding with the
reagent without undergoing covalent reaction and that the loss of water for these ions is
unrelated to Schiff base formation. Subsequent work with tryptic peptides also showed
formation of modified ions with no obvious sites for Schiff base formation in some, but
not all, cases.18 Furthermore, the observation of yn+FBDSA-ions in those peptides that
showed unexpected y♦-ions gave additional evidence for strong electrostatic interactions
that survive collisional activation, even when amide bonds are cleaved.
In this work, we examine the origins of the product ions generated from singly
protonated peptides that undergo charge inversion with doubly deprotonated FBDSA to
shed light on the origins of those products that are inconsistent with Schiff base formation.
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For example, we clarify the nature of the electrostatic interaction involved in the
negatively charged charge inversion product (i.e., interaction between sulfonate and
protonated basic sites, such as arginine, 21,22,23 and/or negatively charged proton-bound
dimer between the sulfonate and the C-terminus or side-chains of Asp or Glu),13,16 as well
as the nature of amino acid side chains in determining the likelihood for the observation
of non-Schiff base dissociation products. To examine the behavior of species with strong
electrostatic binding without the possibility for covalent reactions, we compare data
collected for FBDSA reagent dianions with data collected using doubly deprotonated
benzene disulfonic acid (BDSA). The latter species have been demonstrated to charge
invert peptides and proteins via adduct formation (see reaction (2)).13

[M+H]+ + [BDSA-2H]2- → [M+BDSA-H]-

(2)

These reagent ions have been studied in reactions with model peptides
angiotensin II and YGGFLX, where X is F, K, R, or H, and variations thereof. These
studies have provided a deeper understanding of the nature of the non-covalent reactions
that contribute to stabilizing ion/ion reaction complexes.
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3.2

Experimental Section

3.2.1

Materials

Methanol, glacial acetic acid, acetic anhydride, and ammonium hydroxide were
purchased from Mallinckrodt (Phillipsburg, NJ).

Ammonium bicarbonate, acetyl

chloride, 1,3-benzenedisulfonic acid, 4-formyl-1,3-benzenedisulfonic acid, angiotensin II,
and YGGFL were purchased from Sigma-Aldrich (St. Louis, MO).

The peptides

YGGFLK, YGGFLF, and YGGFLH were purchased from CPC Scientific (San Jose, CA).
The peptide YGGFLR was purchased from Pepnome Ltd. (Zhuhai City, China). All
peptides were used without further purification.

The procedures for N-terminal

acetylation and C-terminal methyl esterification have been previously described. 24
Peptide analytes were prepared at a concentration of ~150 µM in a solution of 50/50 (v/v)
water/methanol prior to positive nanoelectrospray ionization (nESI). The anion reagent,
FBDSA or BDSA, was prepared at a concentration of ~3.5 mM in a solution of
49.5/49.5/1 (v/v/v) water/methanol/ammonium hydroxide for negative nESI.

3.2.2

Mass Spectrometry

All experiments were performed on a 4000 QTRAP QqQ mass spectrometer (AB
Sciex, Concord, ON, Canada), which has been modified for ion/ion reactions. 25
Alternately pulsed nESI emitters allowed for sequential ion injection into the q2 reaction
cell.26,27 Doubly deprotonated reagent anions were ionized first and accumulated in the
q2 reaction cell. Next, peptide cations were generated and transferred to the q2 cell to
undergo a mutual storage reaction for 500-1000 milliseconds. The product ions were
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transferred to the Q3 ion trap, where subsequent MSn analyses and mass analysis via
mass-selective axial ejection (MSAE) were performed.28

3.3

3.3.1

Results and Discussion

Angiotensin II Covalent and Non-Covalent Interactions

The species that was first noted to give rise to an adducted CID product ion that
was inconsistent with Schiff base formation, angiotensin II, is described here to illustrate
the phenomenology and to compare its behavior when reacted with dianions of BDSA.
The ion trap CID of FBDSA- and BDSA-modified angiotensin II (i.e., [M+♦]- and
[M+BDSA-H]-) are shown in Figure 1. In the ion/ion reaction of angiotensin II [M+H]+
with doubly deprotonated FBDSA, a negatively charged complex comprised of the two
reactants (i.e., [M+FBDSA-H]-) is generated.

When this complex is isolated and

subjected to CID, an abundant water loss product is formed. The water loss product is
represented as [M+♦]-, which is consistent with the dehydration reaction that leads to
Schiff base formation. Water loss, however, is a very common process with peptide ions
and does not, in itself, signal the covalent reaction. Subsequent collisional activation of
the dehydration product generates several product ions with mass shifts consistent with
the covalent Schiff base formation or electrostatic modification. These ions are labeled
with the diamond symbol (♦). Ion trap CID of the [M+♦]- ion produces several b♦-ions
(the negative fragment ion nomenclature used here is adapted from protonated peptide
literature[29]) and two y7-related ions (viz., y7♦- and y7+FBDSA-) (Figure 1 (a)). The
presence of b♦-ions in the product spectrum is consistent with the covalent modification
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of the N-terminus, which is the only primary amine site in angiotensin II. The greater
contributions of the b1♦- and b6♦-ions compared to the other b♦-ions can be attributed to
the well-established C-terminal cleavage at aspartate and N-terminal cleavage at the
proline residue.[30,31] The b1♦-ion is particularly noteworthy in that b1-ions are rarely
observed in the CID of unmodified peptide cations or anions.32,33 The presence of the
y7♦-ion is inconsistent with the interpretation that Schiff base formation takes place at the
N-terminus, at least for the fraction of precursor ions that fragment to give this product
ion. This observation led to the hypothesis that some of the [M+♦]- ions were comprised
of attached FBDSA with water loss arising from elsewhere in the peptide.

This

hypothesis requires that the initial [M+FBDSA]- complex can lose water while retaining
an electrostatically bound FBDSA reagent and that subsequent activation of the
electrostatically bound [M+♦]- species can fragment along the peptide backbone while
retaining the adduct. Evidence that both can occur is provided by the product ion that is
consistent with the y7+FBDSA assignment (see Figure 1(a)).
While the above observations are supportive of the hypothesis described above, it
is possible that, for example, arginine might also undergo Schiff base formation, which
could explain the presence of the y7♦-ion, and the signal assigned as y7+FBDSA may
have a different origin. The control experiment with [BDSA-2H]2- as the reagent, which
cannot engage in Schiff base formation, provides further support for the hypothesis. The
reaction of [BDSA-2H]2- with singly protonated angiotensin II produces a negatively
charged, long-lived complex, [M+BDSA-H]-. Ion trap CID of [M+BDSA-H]- is shown
in Figure 1(b). Fragments with an associated double dagger symbol (ǂ) are consistent
with the mass addition of [BDSA-2H]-. The major contribution to the fragmentation
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spectrum is the generation of the y7ǂ-ion, which supports the y7+FBDSA assignment
made in Figure 1(a)

The dehydration product in Figure 1(b) (i.e., the [M+BDSA-H-

H2O]- ion) was isolated and subjected to ion trap CID resulting in formation of both y7ǂ
and y7ǂ-H2O products (Figure 2). The appearance of the y7ǂ-H2O-ion confirms that
dehydration can occur within the y7-ion and fully supports the hypothesis for the origin of
the y7♦-ion in Figure 1(a). The presence of weak signals that correspond to bǂ-ions can be
attributed to an interaction of the BDSA with the protonated arginine, which is the second
residue of angiotensin II, with cleavage C-terminal to the attachment site.

It is

noteworthy that no evidence for b1ǂ-ion formation is apparent in Figure 1(b) while the
b1♦-ion is prominent in Figure 1(a). Covalent modification of the N-terminus in solution
is a strategy that has been used to enhance b1-ion formation in peptide tandem mass
spectra.34,35,36 It is also noteworthy that the [BDSA-H]- signal following CID, which
arises from detachment of the reagent from the complex as a singly charged species due
to proton transfer, is quite small and essentially no evidence for loss of neutral BDSA is
observed. This confirms that cleavage of covalent bonds can be highly competitive with
loss of the non-covalently bound BDSA.37,38,39
The angiotensin II data support the hypothesis that the [M+♦]- species formed
from the dehydration of the [angiotensin II+FBDSA]- adduct is comprised of a mixture of
structures. While the nominal structure of the Schiff base product is clear (i.e. Schiff
base formation at the N-terminus) (see Figure 3(a)), several possibilities exist for the
nature of the electrostatic interaction. One possibility involves the interaction of the
charged guanidinium group of arginine and the anionic sulfonate group on FBDSA (i.e., a
strong acid-base interaction), which is illustrated in Figure 3(b). Another possible non-
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covalent interaction could be the negatively charged proton bound dimer between a
carboxylate group of the peptide and a sulfonate group of FBDSA (i.e., -O3S-C7H5O-SO3--H+---OOC-peptide). A third possibility that is open to disulfonic acid reagents is a
combination of a strong acid-base interaction involving one of the sulfonate groups with
the other sulfonate group being engaged in proton sharing with a carboxylate group (i.e.,
a combination of the two interactions mentioned above). A fourth possibility is a saltbridge structure in which sulfonate and carboxylate groups interact with a protonation site,
depicted here as HO3S-C7H5O-SO3---RH+---OOC-peptide, where R represents the
arginine side-chain. Neither the abundant y7♦- and yǂ-ions nor the bǂ-ions in the spectra
of Figure 1 can be used to distinguish between the four possibilities because of the
aspartic acid residue at the N-terminus and the carboxylate group of the C-terminus.
Therefore, experiments were conducted with protonated methyl esterified angiotensin II
(i.e., both the aspartic acid side-chain and the C-terminus were methyl esterified) in
reaction with [BDSA-2H]2-. This experiment serves to eliminate the possibilities for the
three electrostatic interactions involving carboxylate groups.

Ion trap CID of the

[D(OMe)RVYIHPF(OMe)+BDSA-H]- species generated a spectrum (Figure 4) with
methanol loss being the major process while the generation of [BDSA-H]- and water loss
were observed at lower levels. Very little backbone cleavage was noted, which is in stark
contrast to the data for the unmodified [DRVYIHPF+BDSA-H]- ion (Figure 1(b)). This
result clearly indicates that at least one of the carboxyl groups of angiotensin II plays an
important role in stabilizing the BDSA adduct so that backbone bond cleavage can
compete with loss of BDSA.
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3.3.2

Leucine Enkepalin-Arginine

A series of model peptides based on leucine enkephalin were examined to provide
further insights regarding the nature of the electrostatic binding of FBDSA and BDSA
reagent anions to peptide cations. Figure 5 illustrates the four examples for electrostatic
binding mentioned above for the YGGFLR case. The model peptide YGGFLR was
subjected to charge inversion ion/ion reactions with doubly deprotonated anions derived
either from FBDSA or BDSA and then activated via ion trap CID (Figures 6(a) and 6(b),
respectively). The fragmentation behavior of the modified peptides was also compared to
that of the unmodified deprotonated peptide, [M–H]- (Figure S-7). This peptide was
chosen so that the N-terminus and the arginine residues are at opposite ends of the
sequence.

In the cases of the modified versions of the peptide (i.e., [M+♦]- and

[M+BDSA]-) conditions were used to essentially deplete the precursor ion population
completely (i.e., modifying the activation amplitude to effectively activate and fragment
all of the precursor ion population) to avoid differential sampling of mixtures of
structures, if present, that may have different kinetic stabilities. The [M+♦]- ion was
completely depleted and its location on the mass scale is indicated with an asterisk
symbol (*) in Figure 6(a). Upon collisional activation of [M+♦]-, only N-terminally
modified fragments are observed, which is consistent with covalent modification at the
N-terminus. Many a♦- and b♦-ions along with neutral losses are observed in the product
spectrum, which have been demonstrated previously to be common ion types generated
via collisional activation of the [M+♦]- species of other peptides.17,18 In contrast with the
angiotensin II data, no evidence for electrostatic binding in the [M+♦]- ion is present in
the sequence related product ions, such as y♦-ions. However, a relatively small signal
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consistent with [FBDSA-H]- indicates that a small fraction of the precursor population
may be electrostatically bound and fragments by loss of the neutral peptide, rather than
cleavage of backbone bonds.

Evidence for electrostatic binding and cleavage at

backbone bonds has been observed, however, with arginine-containing tryptic peptides
longer than approximately 8 or 9 residues.18
Charge inversion of YGGFLR via BDSA attachment (Figure 6(b)) illustrates a
marked difference in fragmentation compared to the FBDSA modified peptide. Ion trap
collisional activation of [M+BDSA-H]- produces mainly yǂ-ions, which results from the
interaction of the negatively charged reagent with the C-terminal arginine residue and/or
the C-terminus. This observation differs drastically from the product spectrum of [M+♦]-,
where the product ions are comprised solely of N-terminally modified fragment ions. The
[M+BDSA-H]- data provides further evidence that Schiff base modification is the
dominant process via ion/ion reactions with the reagent FBDSA for YGGFLR. Charge
inversion of YGGFLR via BDSA adduction also produced the most extensive C-terminal
fragmentation in comparison to the other BDSA-modified peptides (Figure 6(b) and
below). Ion trap CID of [M+BDSA-H]- produces mainly yǂ-ions with a high relative
abundance. Most notable is the high contribution of y4ǂ, where the relative abundance is
higher than that of the loss of [BDSA-H]-. In all other model peptides used (i.e., peptides
not containing arginine), the most dominant dissociation pathway occurred via loss of
negatively charged [BDSA-H]- and the generation of the neutral peptide produced by
proton transfer within the long lived complex, as shown in process (3):
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[M+BDSA-H]- → M + [BDSA-H]-

(3)

This observation indicates that the electrostatic interaction between YGGFLR and the
reagent is relatively strong and can compete with the dissociation of covalent bonds upon
collisional activation. Figure 6(c) shows the ion trap CID product ion spectrum of the
methyl esterified version of YGGFLR subjected to charge inversion with BDSA (i.e. CID
of [YGGFLR(OMe)+BDSA-H]-. In this case, process (3) is dominant. Hence, consistent
with the methyl esterification experiment with angiotensin II described above, it is
apparent that the carboxyl group of the C-terminus is involved in the strong electrostatic
binding that allows backbone cleavage to compete with formation of [BDSA-H]- in the
YGGFLR experiment.
The dissociation behaviors apparent in Figures 6(a) and 6(b) are clearly distinct
from one another and illustrate the different ways in which covalent and electrostatic
adduction can alter dissociation patterns. The ion trap CID of the unmodified peptide
anion fragments quite distinctly from either of the modified forms of the peptide (see
Figure 7), as seen previously with other peptide sequences.17,18

Ion trap CID of

deprotonated YGGFLR produces significantly different relative contributions of the c3and b5-ions, as well as the peaks associated with losses from the arginine side chain, such
as loss of HN=C=NH. Ion trap CID of the anions derived from YGGFLH, YGGFLK,
YGGFLF, and YGGFL exhibit the similar marked differences compared to the spectra of
the respective modified species and are also included as Supplemental Information
(Figures 9, 11, 13, 14(c), respectively).
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3.3.3

Leucine Enkepalin-Histidine/Lysine

Other model peptides, such as YGGFLH and YGGFLK, were subjected to ion/ion
reactions to examine the CID behavior of protonated peptides without arginine but with
other basic residues (see Figures 8 and 10, respectively). Ion trap CID of [YGGFLH+♦](Figure 8(a)) produces similar dissociation behavior as YGGFLR (Figure 6(a)). The
major ion-types observed are N-terminally modified fragments, such as a♦- and b♦-ions,
which is consistent with covalent modification of the N-terminus. The relatively small
signal consistent with [FBDSA-H]- is the only indication of electrostatic binding in the
[YGGFLH+♦]- ion population.

Ion trap CID of [YGGFLK+♦]-, on the other hand,

exhibits distinct dissociation behavior from all other model peptides due to the major
contribution of the y♦-ions, especially the contribution of the y4♦-ion (Figure 10(a)).
Collisional dissociation of [YGGFLK+♦]- also produces a b5♦-ion of low abundance.
The peptide YGGFLK contains two primary amines, where one is located at the Nterminus and the other is present at the C-terminal lysine, so the presence of b♦- and y♦ions can both be consistent with Schiff base formation. The preponderance of y♦-ions
suggests that most of the modification in this case takes place at the lysine residue.

A

relatively small signal consistent with [FBDSA-H]- is also observed in the [YGGFLK+♦]spectrum, which is the only clear indication that some of the [YGGFLK+♦]- ions show
electrostatic binding.
The dissociation behavior of BDSA-modified YGGFLH and YGGFLK (Figures
8(b) and 10(b), respectively) exhibit similar characteristics and are also distinct from their
respective [M+♦]- product ion spectra.

The major fragmentation channel following

collisional activation of BDSA-modified YGGFLH and YGGFLK (i.e., [M+BDSA-H]-)
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is the loss of the neutral peptide and generation of [BDSA-H]-. Smaller contributions of
bǂ- and yǂ-ions are noted in both cases. The major sequence-related product ion in both
cases is the y4ǂ-ion. The total signal associated with yǂ-ions is much greater than that for
bǂ-ions, which suggests that the electrostatic binding is largely at the C-terminal basic
residue. However, the fact that any bǂ-ions are noted at all indicates electrostatic binding
at the N-terminus for at least some of the ions. This dissociation behavior of BDSAmodified YGGFLH and YGGFLK is distinct compared to that of BDSA-modified
YGGFLR in that the former show largely loss of the neutral peptide whereas the latter
shows largely backbone cleavages. This is likely due to the stronger interaction of
protonated arginine with sulfonate than either protonated lysine or histidine, in analogy
with solution behavior.

3.3.4

Leucine Enkepalin-phenylalanine and Leucine Enkepalin

The model peptides YGGFLF and YGGFL were subjected to ion/ion reactions to
investigate the behavior of peptide ions without a basic amino acid residue. Ion trap CID
of FBDSA-modified YGGFLF, (i.e., [M+♦]-) exhibits dissociation behavior similar to the
corresponding ions of YGGFLR and YGGFLH in that the product ion spectra are
dominated by N-terminal fragments (see Figure 12(a)). Similar cleavages producing a♦and b♦-ions are observed as well as similar relative contributions, where major
contributions from the b5♦- and b4♦-ions are observed. The results of YGGFL (Figure
14(a)) are highly analogous to those of YGGFLF.

The CID product spectrum of

[YGGFL+♦]- produces all N-terminal fragments, which is consistent with the expectation
that the covalent modification takes place at the N-terminus. The only evidence for a
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contribution from ions with an electrostatic interaction comes from a minor signal
consistent with [FBDSA-H]-.
Collisional activation of the electrostatic complex (i.e., [M+BDSA-H]-) for
YGGFLF (Figure 12(b)) leads to similar dissociation behavior as that noted for the
analogous species from YGGFLH and YGGFLK. Loss of [BDSA-H]- again is the
dominant dissociation pathway generated via ion trap CID of BDSA-modified YGGFLF
and the major backbone cleavage yields the y4ǂ-ion.
[YGGFLF+H]+/[BDSA-2H]2-

experiment

are

also

The results from the

highly

illustrative

of

the

[YGGFL+H]+/[BDSA-2H]2- experiment (Figure 14(b)). Ion trap CID of BDSA-modified
YGGFL predominantly leads to [BDSA-H]- and the most abundant backbone fragment
arises from cleavage of the analogous peptide linkage, which leads to a y3ǂ-ion for this
shorter peptide. Data were also collected for cations of N-terminally acetylated YGGFL,
methyl-esterified YGGFL, and YGGFL with both N-terminal acetylation and C-terminal
methyl-esterification, in reaction with doubly deprotonated [BDSA-2H]2-. In all cases,
[M+BDSA-H]- ions were formed and, in all cases, ion trap collisional activation led to
strongly dominant [BDSA-H]- formation (see Figure 15). Collectively, the experiments
with the YGGFLX model ions clearly show that strong electrostatic binding involving the
BDSA anions takes place with peptide cations and that collisional activation of the
electrostatically-bound cations can give rise to competitive backbone cleavage. However,
backbone cleavage is most strongly competitive, by far, when arginine is present and at
least one carboxyl group are both present in the peptide. In all other cases, loss of the
peptide and formation of the BDSA anion is the most favored process. The dissociation
behavior of BDSA-modified methyl esterified model peptides (i.e., YGGFLR-OMe and
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YGGFL-OMe) demonstrates the increased strength of the electrostatic interaction
between the carboxyl groups and the reagent anion. This set of observations points to the
importance of the interactions that involve both the protonated site of the peptide and a
carboxyl group of the peptide (i.e., structures (c) and (d) of Figure 3).

3.4

Conclusions

These studies have added new insights into the nature of the non-covalent
interactions of benzene disulfonic acid anions with peptide cations. The substitution of
two sulfonic acid groups on the ring of benzaldehyde (i.e., FBDSA) has proved to be
important in the observation of gas-phase Schiff base formation involving primary
amines in peptide ions. These studies have confirmed earlier speculation that noncovalent interactions in the peptide-BDSA/FBDSA complex can be sufficiently strong to
allow covalent bond cleavage to compete with loss of BDSA/FBDSA as an anion or
neutral.

Such an interpretation was forthcoming from the observation of adduct-

containing fragments that did not contain a primary amine for Schiff base formation.
Studies with model protonated YGGFLX peptides clearly show that two criteria greatly
facilitate the observation of covalent bond cleavage versus disruption of non-covalent
binding. These include the presence of arginine, which gives rise to the strongest acidbase interaction of all of the basic side chains, and the presence of a carboxyl group,
which can engage in proton sharing with a sulfonate group or stabilize a salt-bridge
interaction. While the data presented here cannot be used to distinguish the latter two
possibilities, our experience with benzene sulfonic acid (i.e., a single sulfonate group
present on the reagent anion) in reaction with multiply protonated peptides (data not
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shown), which should be able to undergo a salt-bridge type interaction, show dominant
loss of the reagent from complexes with the peptide. This leads us to favor the combined
acid-base/proton-bound dimer interaction involving both sulfonate groups (i.e., the
interaction of structure (c) in Figure 5).
The improved understanding derived from this work regarding the nature of noncovalent interactions in ion/ion chemistry is useful in considering the design of reagents
for specific purposes. For example, the ‘tuning’ of binding strength between reagent and
analyte ion via control over the identities of functional groups in both the analyte and
reagent can be used to either enhance or minimize particular reaction channel types. For
example, it may be possible to increase the cleavage of covalent bonds in ion/ion adducts
by incorporating an additional sulfonate group in the reagent. It might also be possible to
minimize covalent bond cleavage in arginine containing peptides by using a reagent
dianion with one sulfonate group and one carboxylate group instead of two sulfonate
groups. This work has indicated, for example, that contributions from covalent bond
cleavage from electrostatically bound adducts can be minimized by esterification of the
peptide carboxyl groups.

The results reported here, therefore, provide useful new

insights in the design and application of reagents for gas phase ion/ion reactions.

Reprinted (adapted) with permission from Stutzman, J. R.; Luongo, C. A., McLuckey, S.
A. J. Mass Spectrom. 2012, 47, 669-675. Copyright (2012) Journal of Mass Spectrometry.
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Figure 3.1: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]-, M = angiotensin II
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Figure 3.2: Ion trap CID product ion spectrum of [M+BDSA-H-H2O]-, derived from M =
angiotensin II (DRVYIHPF).
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Figure 3.3: Ion population of [M+♦]-, a) Schiff base formation with singly protonated
angiotensin II and doubly deprotonated FBDSA, b) One of the possible strong
electrostatic interactions that may play a role in the observation of the y7♦-ion of Figure
1(a). This interaction involves a deprotonated sulfonate group on FBDSA and the
charged guanidinium side chain of arginine.
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Figure 3.4: Ion trap CID product ion spectrum of the BDSA adduct of methyl esterified
angiotensin II (D(OMe)RVYIHPF(OMe)), i.e., [M+BDSA-H]-.
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Figure 3.5: Four examples of possible non-covalent interactions between protonated
YGGFLR and the dianion of BDSA. (a) Strong acid-base interaction. (b) Negatively
charged proton-bound dimer. (c) Combined strong acid-base and proton-bound dimer
interactions. (d) Salt-bridge interaction.
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Figure 3.6: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]-, c) methyl esterified YGGFLR-BDSA adduct,
[YGGFLR(OMe)+BDSA-H]-.
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Figure 3.8: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]- derived from M = YGGFLH
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Figure 3.9: Ion trap CID product ion spectrum of [M-H]- derived from M = YGGFLH.
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Figure 3.10: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]- derived from M = YGGFLK
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Figure 3.11: Ion trap CID product ion spectrum of [M-H]- derived from M = YGGFLK.
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Figure 3.12: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]-, derived from M = YGGFLF
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Figure 3.13: Ion trap CID product ion spectrum of [M-H]- derived from M = YGGFLF.
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Figure 3.14: Ion trap CID product ion spectra of a) FBDSA-modified product, [M+♦]-, b)
BDSA-modified product, [M+BDSA-H]-, and c) the deprotonated molecule [M-H]derived from M = YGGFL.
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Figure 3.15: Ion trap CID product ion spectra of a) [ac-YGGFL+BDSA-H]-, b) [YGGFLOMe+BDSA-H]-, and c) [ac-YGGFL-OMe+BDSA-H]-.
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CHAPTER 4. ION/ION REACTIONS OF MALDI-DERIVED PEPTIDE IONS:
INCREASED SEQUENCE COVERAGE VIA COVALENT AND
ELECTROSTATIC MODIFICATION UPON CHARGE INVERSION

4.1

Introduction

Peptide sequencing for identification and structural characterization of proteins is
a longstanding activity in molecular biology research.

1

Matrix-assisted laser

desorption/ionization (MALDI)2,3 and electrospray ionization (ESI)4, two very successful
means for the derivation of gas phase ions from proteins and peptides, coupled with
tandem mass spectrometry, have become the dominant tools for generating sequence
information from mixtures of peptides.5,6,7,8 While there is significant overlap, ESI and
MALDI have each found applications for which they are best suited.9 For example, ESI
has been widely used to interface on-line liquid separations with mass spectrometry,
whereas MALDI is widely used for sampling surfaces, as in imaging applications.
MALDI has been adapted to several tandem MS instrument geometries, e.g. tandem
time-of-flight (i.e., TOF/TOF), 10 quadrupole/time-of-flight (i.e., Q/TOF), 11 and ion
trap 12 , 13 , 14 analyzers.

The appeal of ion trap technology is that it permits MSn

experiments to be conducted on MALDI-derived biomolecule-ions.15,16
From the standpoint of sequencing, a significant difference between MALDI and
ESI is their propensities for generating multiply charged ions. Under commonly used
conditions, MALDI generates ions of lower charge than does ESI. In fact, for peptides,
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singly charged ions usually dominate.

Low energy collisional activation of singly

protonated tryptic peptides, however, often does not produce extensive sequence
information. 17 , 18 Dissociation behavior is dominated by low energy fragmentation
pathways, e.g. cleavage C-terminal to an aspartic acid residue or N-terminal to a proline
residue.19 Furthermore, MALDI-derived tryptic peptides may generate limited sequence
information due to the basic residue present at the C-terminus.20,21,22 Tryptic peptides
often generate fragment ions associated with the C-terminus (e.g. y-ions) as a result of the
C-terminal lysine or arginine sequestering the excess proton.20 A variety of approaches
have been attempted to improve peptide sequencing in conjunction with MALDI.

For

example, condensed-phase peptide modification, such as fixed-charged derivatization of
the N-terminus, has been attempted with mixed success.23,24 A noteworthy approach,
developed by Keough et al., to increase sequence information from the dissociation of
MALDI-derived tryptic peptides involved conjugating a sulfonic acid group to the Nterminus via solution phase chemistry. 25,26 The objective was to alter fragmentation
pathways by introducing a highly acidic group into the peptide. Fragmentation was
dramatically improved in derivatized tryptic peptides compared to the underivatized
tryptic peptides. However, the N-terminal position of this modification precluded the
presence of N-terminal fragments due to the anionic sulfonate group.26
We and others have been developing approaches to modify ions in the gas phase
and within the context of a tandem mass spectrometry experiment (i.e., modification of
mass-selected ions) to expand the capabilities of tandem mass spectrometry for ion
structure characterization using ion/ion reactions. 27 Ion/ion reactions can be used to
decouple the ion-type initially generated by the ionization method from the ion-type
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subjected to tandem mass spectrometry.

28

Structural information derived from

fragmentation is highly dependent upon the nature of the ion (e.g., positive ion vs.
negative ion, even-electron ion versus odd-electron, etc.).29 Therefore, ion/ion reactions
can expand the range of ion-types that can be subjected to tandem mass spectrometry
relative to the ion-types available from the ionization method. For example, ion/ion
reactions have been used to manipulate peptide ion charge state30,31 and polarity32,33,34 via
the transfer of one or more protons, generate odd-electron ions from even-electron ions
via electron transfer,35,36 and insert metal ions into polypeptides.37 Recent studies have
demonstrated the alteration of peptide dissociation behavior via the gas phase
electrostatic attachment of reagents34,38 and via the gas phase covalent modification of
peptide ions. 39 , 40 , 41 All such examples to date have been restricted to peptide ions
generated via ESI.
In this work, we demonstrate the gas phase modification of peptide ions generated
by atmospheric pressure MALDI (AP-MALDI)42 using a dual source interface developed
by Schneider et al.43 attached to a hybrid triple quadrupole/linear ion trap tandem mass
spectrometer and the structural characterization of the modified and unmodified versions
of the ions via ion trap CID. The formation of imine bonds (i.e. Schiff base formation)
using an aldehyde containing dianion, 4-formyl-1,3-benzenedisulfonic acid (FBDSA)44,45
has been demonstrated with peptide ions generated via ESI. Possible sites of peptide
covalent modification are the N-terminus and the ϵ-NH2 of lysine. Strong non-covalent
interactions (i.e. electrostatic modification) have also been observed between the
sulfonate groups of FBDSA and peptides containing an arginine residue and one or more
carboxyl groups.38 Covalent bond cleavage is competitive with disruption of this strong
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electrostatic interaction under collisional activation conditions.

In either case (i.e.,

covalent modification or strong electrostatic binding), the reaction product is a singly
charged anion. The overall approach described here differs from the Keough et al.
approach in that singly charged anions are subjected to CID, rather than singly charged
cations, but is similar in that sulfonate is introduced into the peptide to alter dissociation
behavior. Ion/ion reactions have been performed on tryptic peptides of ubiquitin and two
synthetic peptides, APPGFSPFR and GLSDGEWQQVLNVWGK. Collisional activation
of modified tryptic peptide anions demonstrates modification of the primary amine at the
N-terminus and the C-terminal basic residue. Such modifications produce both modified
N- and C-terminal fragment ions compared to the solely C-terminal information observed
by Keough. Ion trap CID of the modified anions is shown to generate more sequence
information than the unmodified ion, especially in the form of b-type ions. This study
represents the first demonstration of gas phase modification of MALDI-derived ions via
ion/ion reactions.

4.2

Experimental Section

4.2.1

Materials

Trifluoroacetic acid (TFA) was purchased from Pierce (Rockford, IL). Ubiquitin
from bovine erythrocytes, TPCK treated trypsin from bovine pancreas, alpha-cyano-4hydroxycinnamic acid (CHCA), FBDSA, and ammonium bicarbonate were purchased
from Sigma-Aldrich (St. Louis, MO). Synthetic peptides APPGFSPFR and
GLSDGEWQQVLNVWGK were purchased from SynPep (Dublin, CA).

Peptides
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MQIFVK, TITLEVEPSDTIENVK, EGIPPDQQR, LIFAGK, TLSDYNIQK, and
ESTLHLVLR were generated from a tryptic digestion of ubiquitin.

4.2.2

Methods

The MALDI matrix, CHCA, was prepared in 39.5/59.5/1 (v/v/v)
water/acetonitrile/TFA at a concentration of 10 mg/mL. Peptide analytes were prepared
in a ~100 µM aqueous solution prior to a 50/50 (v/v) mixture with the MALDI matrix
solution. 2.0 µL of the matrix/analyte solution was spotted onto the MALDI stage plate
and allowed to air-dry prior to attachment to the AP-MALDI source. The anion reagent
was composed of a 3.5 mM solution of 50/50 (v/v) water/acetonitrile for negative microionspray.

4.2.3

Tryptic Digest

The procedure for the tryptic digest of ubiquitin has been described previously.46
Separation of the tryptic peptides was performed on a reverse-phase HPLC (Agilent 1100,
Palo Alto, CA) using an Aquapore RP-300 (7µm pore size, 100 x 4.6 mm i.d.) column
(Perkin-elmer, Wellesley, MA).
described previously.46

The gradient for the HPLC separation has been

Following HPLC separation, the collected fractions were

concentrated and reconstituted in 200 µL of water.
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4.2.4

Mass Spectrometry

Experiments were performed on a 4000 AB Sciex QTRAP (Concord, ON,
Canada), which has been modified to perform ion/ion reactions. 47 The ion source is
equipped with an AP-MALDI source (MassTech, Columbia, MD) and with a microionspray emitter (New Objective Inc, Waburn, MA) orthogonal to the sample inlet
(Figure 1).43,48 The micro-ionspray emitter, remote to the MS inlet and MALDI stage
plate, allows for the introduction of opposite polarity ions into the MS. Briefly, the APMALDI source has a circular opening, where a conductive transfer tube penetrates into
the ion source and attaches to the curtain plate. The micro-ionspray is directed towards
the transfer tube and upon ionization/nebulization, ions travel into the transfer tube and
the ion source.
The reagent anion, doubly deprotonated FBDSA, was generated via microionspray at a continuous flow rate of 8.0 µL/min from a silica sprayer (364 µm outer
dimension, 48 µm inner dimension, Polymicro Technologies, Phoenix, AZ). N2 acts as
the nebulizing gas, which helps guide the reagent anions into the ion source. The
nebulizing gas was triggered/pulsed via MS Expo software (AB Sciex, Concord, ON,
Canada) during negative ion injection conditions. Once doubly deprotonated FBDSA
entered the MS, it was transferred to the q2 collision cell and stored. Tryptic peptides,
individually spotted in CHCA, were ablated via a 337-nm nitrogen laser (AP-MALDI Ion
Source 110, MassTech, Columbia, MD) and transferred to the q2 collision cell to undergo
ion/ion reactions with the reagent anions. 49,50 In the peptide mixture study, multiple
peptides from the reconstituted solutions were spotted on the MALDI stage plate with
CHCA. All cations produced via MALDI in the mixture study were transferred to q2
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without mass discrimination and reacted with FBDSA dianions. Product ions generated
in q2 were transferred to Q3 for further collisional activation and subsequent mass
analysis.51

4.3

Results and Discussion

Ubiquitin was subjected to tryptic digestion and the tryptic peptides MQIFVK,
TITLEVEPSDTIENVK, EGIPPDQQR, LIFAGK, TLSDYNIQK, and ESTLHLVLR
were collected. The MALDI-derived tryptic peptide ions were subjected to ion/ion
reactions with doubly deprotonated FBDSA. The main product of the ion/ion reaction is
a negatively charged, long-lived complex comprised of the reagent dianion and tryptic
peptide cation. The complex is formed when a negatively charged sulfonate interacts
strongly with a protonated site on the peptide. The aldehyde group of the reagent
undergoes nucleophilic attack by a neutral primary amine of the peptide during
collisional activation of the complex leading to the formation of an imine bond (i.e.,
Schiff base) and loss of a water molecule. The Schiff base product anion is represented
in spectra by [M+♦]-. The process of forming a Schiff base via gas phase ion/ion
reactions is depicted in process (1):

[M+H]+ + [FBDSA-2H]2- → [M+FBDSA-H]- → [M+♦]- + H2O

(1)

The diamond symbol (♦) represents the mass addition of the reagent anion following a
water loss. Fragments that are consistent in mass with those that retain the covalent
modification are labeled with the diamond. The negative ion mode post-ion/ion reaction
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spectrum (Figure 2(a)) and positive MALDI mass spectrum of a mixture of three tryptic
peptides (viz., LIFAGK, EGIPPDQQR, and TLSDYNIQK) are compared in Figure 2.
Figure 2(a) was generated by exposing peptide cations of Figure 2(b) to reaction with
doubly deprotonated FBDSA.

The ion/ion reaction generated a product spectrum

containing primarily the intact complex (i.e., [M+FBDSA]-) and signals due to [M+♦]- of
much lesser abundance. The [M+♦]- ions were likely generated by CID upon transfer
from q2 to Q3. Subsequent isolation and activation of the [M+FBDSA]- ion generates
abundant [M+♦]- for subsequent interrogation. Contributions from strong electrostatic
binding of the reagent were much more apparent in the data for the arginine terminated
peptides than for the lysine terminated peptides (vide infra). For this reason, results from
lysine and arginine terminated peptides are presented separately.

4.3.1

Lysine Terminated Tryptic Peptides

Ion trap CID spectra of protonated TITLEVEPSDTIENVK and the modified
peptide anion (i.e. [M+H]+ and [M+♦]-, respectively) are compared in Figure 3.
Collisional activation of [M+H]+ leads to nine of fifteen amide bond cleavages,
producing eleven fragment ions (Figure 3(b)). Fragmentation of the singly protonated
peptide produces limited sequence informative ions as well as non-informative neutral
losses.

The product ion spectrum produces relatively large contributions from the

fragment ions y6 and y9. The fragment ion y6 arises from the well-established C-terminal
cleavage of aspartic acid,52 while the fragment ion y9 originates from the well-established
N-terminal cleavage of the proline residue.53 Dominance of low-energy fragmentation
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pathways has been frequently observed in tandem MS experiments with MALDI-derived
peptide cations.19

When compared to b-ions, the y-ions clearly dominate the

fragmentation spectrum of the unmodified cation. Collisional activation of the peptide
cation produced only four b-ions compared to seven y-ions.

Limited N-terminal

information (e.g. b-ions) from the collisional activation of [M+H]+ can be explained by
the presence of a C-terminal basic lysine residue as reported by Biemann.20
Collisional activation of modified TITLEVEPSDTIENVK (Figure 3(a)) produces
distinct dissociation behavior compared to the unmodified spectrum. In the product ion
spectrum, the most abundant peaks are associated with modified b- and y-ions, which are
represented as b♦ or y♦. The nomenclature of modified fragment anions is adapted from
the peptide literature for protonated peptides.54 The b♦-ions are interpreted to arise from
a covalent modification of the N-terminus, while the y♦-ions are interpreted to arise from
the covalent modification of the ϵ-NH2 of lysine. Collisional activation of the modified
peptide anion produces a higher degree of fragmentation than the unmodified peptide
cation, where twelve of fifteen amide bonds are cleaved, generating a total of sixteen
fragment ions and a significant increase in N-terminal information. In the spectrum of
the modified ion, seven b♦-ions are produced compared to four b-ions in the spectrum of
the unmodified peptide. We note that previous studies have clearly shown that [M+♦]ions yield significantly more sequence information upon CID than the corresponding [MH]- ions.38,44,45 The incorporation of the two sulfonate groups into the peptide is expected
to have a significant impact on proton mobility within the anion, which influences the
favored dissociation pathways. This may favor charge remote processes55,56 or it may
require the ions to be elevated to higher energies in order to promote intramolecular
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transfer. In any case, the disulfonic acid modification to the peptide has been shown to
lead to consistently greater sequence coverage than singly charged versions of the
unmodified peptide (i.e., [M+H]+ or [M-H]-).38,44,45 Furthermore, modification at the Nterminus gives rise to much greater contributions from anionic b♦-ions, which are not
readily observed without the modification. Ion trap CID of [M+♦]- also appears to have
less selective cleavage along the peptide backbone compared to the peptide cation, which
has been observed in previous studies.45
Another ubiquitin tryptic peptide with a C-terminal lysine, TLSDYNIQK,
produced results similar to those noted for the peptide TITLEVEPSDTIENVK. Ion trap
CID of modified TLSDYNIQK (i.e. [M+♦]-) produced a high degree of sequence
information, where a cleavage at every amide bond is observed (Figure 4(a)). The
presence of many b♦- and y♦-ions is consistent with the covalent modification of the Nterminus and ϵ-NH2 of lysine. The high relative contribution of b4♦ in the product ion
spectrum is attributed to the labile C-terminal cleavage of aspartic acid.52 The presence
of b1♦ is particularly noteworthy because the b1-ion is not typically observed in the
collisional activation of unmodified protonated and unprotonated peptides.57,58 Ion trap
CID of the singly protonated peptide generates a product ion spectrum with seven of
eight amide bond cleavages (Figure 4(b)); however, many less informative fragment ions
are also observed in the spectrum (e.g., internal fragments and neutral losses). The
product spectrum of the unmodified peptide cation is dominated by the C-terminal
cleavage of aspartic acid, generating the highly abundant y5-ion.

Conversely, the

modified anion appears to fragment more uniformly. Dissociation of the peptide cation is
dominated by the generation of y-ions, while the presence of b-ions is limited. The
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modified peptide anion produces a significant number of b♦-ions and an even higher
number of y-type ions due to the presence of y1♦ and y2♦. With a near doubled increase
of y-and b-type ions (i.e. thirteen versus seven fragment ions), the modified peptide ion
clearly produced more sequence information compared to the unmodified peptide.
The peptides TITLEVEPSDTIENVK and TLSDYNIQK are illustrative of the
synthetic peptide GLSDGEWQQVLNVWQK. Collisional activation of the modified and
unmodified GLSDGEWQQVLNVWQK is provided below (Figure 5). Ion trap CID of
[M+♦]- produces a high order of b♦- and y♦-ions (Figure 5(a)), while the protonated
peptide produces limited b- and y-ions (Figure 5(b)). The modified peptide anion again
produced a higher order of sequence information than the unmodified peptide cation.
However, the aforementioned lysine containing peptides are not necessarily illustrative of
low m/z peptides, such as MQIFVK (Figure 6) and LIFAGK (Figure 7).
Ion trap CID of modified MQIFVK (i.e. [M+♦]-) produces mainly y♦-ions at
four of the five amide bond cleavages (Figure 6 (a)) and only one ion in the b♦-ion series
(i.e., the b♦5-ion), which is distinct from the observation of many more b♦-ions from the
large modified peptide ions (i.e. TITLEVEPSDTIENVK, TLSDYNIQK, and
GLSDGEWQQVLNVWQK). Ion trap CID of the unmodified peptide cation produces
many b- and y-ions, which account for four of the five amide bond cleavages (Figure
6(b)).

Smaller peptide ions tend to yield more extensive sequence information in

general.17

While similar amide bonds are cleaved in the modified and unmodified

peptide ions, there is a degree of complementarity from the two peptide ion-types. The
modified anion produces lower m/z y♦-ions, while the [M+H]+ produces mainly b-ions.
Also, the relative contributions of the fragment ions in the product ion spectra are
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markedly different. The modified peptide ion produces a highly abundant y3♦-ion, and
the peptide cation generates a highly abundant internal fragment ion, showing the distinct
dissociation behavior. The results from the peptide MQIFVK are illustrative of the
peptide LIFAGK (Figure 7). Ion trap CID of [LIFAGK+♦]- produces mainly modified
y♦-ions, which is consistent with the covalent modification of the ϵ-NH2 of lysine.
Collisional activation of the unmodified peptide cation produces a-, b-, and y-ions. Ion
trap CID of both the modified and unmodified versions of LIFAGK displays a degree of
complementarity, much like MQIFVK.

4.3.2

Arginine Terminated Tryptic Peptides

Previous studies of the ion trap CID of modified arginine containing peptides (i.e.
angiotensin II (DRVYIHPF) and ubiquitin tryptic peptides) demonstrated product ion
spectra consistent with two product populations: Schiff base formation and non-covalent
binding of the reagent to the guanidinium side chain of arginine.39,45 Product ion spectra
showed the appearance of y♦-ions; however, the only primary amine in the peptide
capable of engaging in Schiff base formation was the N-terminus. The y♦-ions were
determined to arise from [M+♦]- ions composed of an electrostatic interaction with the
arginine guanidinium side chain.

The water loss leading to the nominal [M+♦]-

originated from elsewhere in the peptide (i.e., it was unrelated to the reagent). The
presence of y+FBDSA-ions also provided evidence of an electrostatic rather than a
covalent interaction.

Model systems (i.e. YGGFLX peptides) further demonstrated

strong interactions between the sulfonate groups and peptides containing an arginine
residue and one or more carboxyl groups (e.g. C-terminus) in the gas phase.38 These non-
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covalent interactions with FBDSA dianions are sufficiently strong that covalent bond
cleavage can compete with reagent detachment upon collisional activation.38,45
Ion trap CID of modified EGIPPDQQR is displayed in Figure 8(a). Collisional
activation of the modified anion generated fragment ions consistent with covalent and
electrostatic modifications. The presence of b♦-ions is consistent with the covalent
modification of the N-terminus, while y♦ and y-FBDSA-ions are consistent with an
electrostatic attachment to the peptide (e.g. reagent interaction with arginine and Cterminus). The presence of y♦-ions can be attributed to the electrostatic attachment of the
FBDSA dianion to the C-terminal arginine and a water loss within the fragment ion (e.g.
aspartic acid residue). The loss of [FBDSA-H]- also indicates an electrostatic interaction
between the analyte and reagent. The loss of [FBDSA-H]- generates a neutral dehydrated
peptide due to proton transfer within the complex, as seen in process (2).

[M+FBDSA-H-H2O]- → M-H2O + [FBDSA-H]-

(2)

The high relative abundances from [FBDSA-H]- and y3+FBDSA are particularly
noteworthy. The significantly higher relative abundance of y3+FBDSA than [FBDSAH]- suggests that the electrostatic interaction can compete with cleavage of covalent
bonds upon collisional activation. Such a competition gives rise to the y♦ and y-FBDSAions.
Collisional activation of the modified anion produces a higher order of sequence
information than the peptide cation. The modified anion produces a mixture of ten
y+FBDSA and y♦-ions, and when combined, the mixture produces seven of the eight
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possible C-terminal amide bond cleavages. The modified peptide also produces more Nterminal fragments, i.e., b3♦, b6♦, and b8♦, relative to the unmodified peptide cation.
Collisional activation of the singly protonated EGIPPDQQR produces limited sequence
information in comparison to the modified version, as seen previously. The unmodified
cation produces mainly y-ions, while only a single b-ion was produced. Dissociation of
the peptide cation is dominated by cleavage C-terminal to the acidic residues, i.e., the y3and y8-ions, as seen in many MALDI-derived MS/MS experiments. Activation of the
unmodified peptide cation produces similar y-type ions to the modified version, while the
modified anion produces lower m/z y-type ions that the unmodified version lacks.
Ion trap CID of the modified and unmodified synthetic tryptic peptide,
APPGFSPFR, is illustrated in Figure 9. The modified anion produces cleavages at all
eight amide bonds, and the most notable observation in the product ion spectrum is the
generation of a b♦-ion at each peptide bond (Figure 9(a)), including the b1♦-ion.
Collisional activation of [M+♦]- produces a combination of y♦- and y+FBDSA-ions. The
product ion spectrum shows a high contribution from the well-established N-terminal
cleavage of the proline residue (i.e. b6♦-H2O); however, more uniformity of cleavage
among amide bonds is observed compared to the unmodified cation. While the ion trap
CID of [M+H]+ (Figure 9(b)) and [M+♦]- produces similar higher m/z y-type product ions,
the modified anion also produces lower m/z modified y-ions (i.e. y1+FBDSA). The most
noteworthy observation of the product ion spectra is the drastic difference between the Nterminal fragment ion information. Collisional acitivation of the peptide cation produces
only three b-ions, while the modified anion produces eight b♦-ions. The presence of the
b♦-ions significantly increases the observed sequence information.

The results of
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EGIPPDQQR and APPGFSPFR are illustrative of ubiquitin tryptic peptide ESTHLVLR
(Figure 10). Ion trap CID of [ESTHLVLR+♦]- produces a mixture of y♦- and y+FBDSAions along with higher m/z b♦-ions. The unmodified peptide cation produces similar band y-type ions; however, the modified anion additionally produces lower m/z modified
y-ions, i.e. y1+FBDSA.
We note that many of the singly protonated peptides derived by MALDI and
subjected to ion/ion reactions in this work have also been derived via electrospray and
subjected to reactions with the same reagent.45 Very similar product ion spectra were
derived from the same peptide ions derived by these two ionization methods. Not
surprisingly, the main difference in the two approaches was that singly protonated
peptides dominated in all cases in the MALDI experiment, whereas multiply protonated
peptides were the major ions noted for the larger peptides in the electrospray experiment.

4.4

Conclusions

Covalent and electrostatic modification of MALDI-derived tryptic peptide cations
via gas phase ion/ion reactions with doubly deprotonated FBDSA has been demonstrated.
Covalent modification is observed at the N-terminus and ϵ-NH2 of lysine for lysine
terminated tryptic peptides.

Covalent and electrostatic modification is observed for

arginine terminated tryptic peptides, where the covalent modification occurs at the Nterminal primary amine and electrostatic modification occurs at the C-terminal arginine
residue. Both modified lysine and arginine terminated tryptic peptides have shown to
result in increased sequence information upon collisional activation compared to the
unmodified version in high m/z peptides (>1000 Th). Ion trap CID of the modified
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anions generally shows an increase in the relative contribution of b-type ions, where
unmodified peptide cations have shown limited b-ions. In many cases, the modified
anion produces sequence-informative y-ions of lower m/z that are often not observed
from the unmodified peptide cation. In general, modified anions have shown more
uniform fragmentation compared to the unmodified cations, which often show dominant
cleavages due to low energy CID pathways. This study demonstrates the first example of
gas phase ion/ion reactions involving MALDI-derived ions (other than those that may
occur inherently in the MALDI process). In this case, we demonstrate the gas phase
modification of the ions to improve the MS/MS performance of MALDI-derived tryptic
peptides without recourse to solution phase chemistry.

Reprinted (adapted) with permission from Stutzman, J. R.; McLuckey, S.A. Anal. Chem.
2012, 84, 10679-10685. Copyright (2012) American Chemical Society.
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Figure 4.1: Modified AP-MALDI source, attached to a QTRAP 4000, capable of
multisource injection.
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Figure 4.2: a) Ion/ion product spectrum of peptide cation mixture and [FBDSA-2H]-2 b)
Positive ion spectrum of peptide mixture LIFAGK, EGIPPDQQR, and TLSDYNIQK
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Figure 4.3: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
TITLEVEPSDTIENVK
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Figure 4.4: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
TLSDYNIQK
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Figure 4.5: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
GLSDGEWQQVLNVWGK
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Figure 4.6: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
MQIFVK
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Figure 4.7: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
LIFAGK
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Figure 4.8: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
EQIPPDQQR
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Figure 4.9: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
APPGFSPFR
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Figure 4.10: Ion trap CID product ion spectra of (a) [M+♦]- (b) [M+H]+ derived from M=
ESTLHLVLR
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CHAPTER 5. SCHIFF BASE REAGENT CLUSTER ANIONS FOR MULTIPLE GASPHASE COVALENT MODIFICATIONS OF PEPTDIES AND PROTEIN
CATIONS

5.1

Introduction

Mass spectrometry and tandem mass spectrometry have pivotal roles in the
identification and structural characterization of peptides and proteins as such information
provides insight on their physiological roles. 1,2 Chemical derivatization of biological
macromolecules has been performed so as to facilitate ionization,3 quantification,4,5 and
characterization. 6 , 7 Recently, bioconjugation techniques have exploded in popularity,
especially in the area of characterization, due to the insight it provides in proteomics. For
instance, N-hydroxysuccinimide (NHS) esters have been utilized to determine the relative
reactivates of primary amines in denatured and native-state ubiquitin.8 In addition to
determining the relative reactivities, NHS crosslinking reagents have been utilized to
elucidate the higher order structure of proteins.9,10,11 Chemical derivatization has also
been used to bioconjugate chromophores to enable photodissociation processes.12
While these approaches have been restricted to the solution phase, ion/ion
chemistry has afforded bioconjugation techniques to be performed in the gasphase.13,14,15,16 Covalent ion/ion chemistry has many inherent benefits over the solution
phase reactions: speed (100s of milliseconds), quick comparison between modified and
unmodified ions, high degree of control over reactants via mass selection, ability to
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control the number of modifications, avoidance of complex reaction mixtures, etc. 17
Recent demonstrations of bioconjugation chemistries include NHS,14,15 Schiff base,13,18
and carbodiimide covalent chemistry.16 NHS esters have been utilized to tag primary
amines as well as unprotonated arginine residues in the gas-phase.14,15 NHS crosslinking
reagents have been used to crosslink gaseous peptide chains19 as well as ubiquitin to
determine the relative reactivity of each primary amine and the overall three dimensional
structure.20 Gas-phase crosslinked ubiquitin has displayed similar dissociation behavior
as the solution phase method, providing a faster and more efficient method to perform
this bioconjugation chemistry.

In addition, the Schiff base reagent 4-formyl, 1, 3-

benzene disulfonic acid (FBDSA) has been extensively investigated as a derivatization
agent of unprotonated primary amines.21,22,23 Gas-phase Schiff base chemistry has shown
the ability to increase primary sequence coverage in various biological macromolecules
in the context of a ion/ion charge inversion experiment.18,21,23 All of the gas-phase
covalent chemistry mentioned thus far has been restricted to primary amines.

N-

cyclohexyl-N’-(2-morpholinoethyl)carbodiimide (CMC) has demonstrated the ability to
covalently modify carboxylic acid functionalities present in peptides and dendrimers.16
Covalent chemistry in the gas-phase proceeds through a long lived complex,
comprised of the reagent and analyte ions (at least one must be multiply charged). The
sufficiently long lifetime allows for multiple interactions to occur so as to generate a
chemical reaction. For example, FBDSA modification proceeds via a nucleophilic attack
of a primary amine on the aldehyde carbonyl carbon of FBDSA, where a rearrangement
occurs causing the loss of water and formation of an imine bond.13,18 The extent to which
gas-phase modification can be performed on a system is limited by the number of

119
available reaction sites in the analyte and the initial charge state of the analyte. In some
situations, it may be desirable or advantageous to modify multiple reactive sites; however,
the initial charge of the analyte ion may be too low to allow consecutive ion/ion reactions
prior to neutralization. Ultimately, the number of covalent modifications that can be
performed on [M+nH]n+ is limited to one less than the total charge, i.e. n-1. Therefore, it
is of interest to develop a method to perform multiple covalent modifications within a
single ion/ion reaction.
In this study, we demonstrate the ability to perform multiple covalent
modifications within one ion/ion encounter via reagent ion clusters. The reagent clusters
are comprised of n reactive reagent anions and n-1 counter cations; generating an overall
singly charged anion. Specifically, 2-formyl-bezenesulfonic acid reagent anion clusters
are reacted with protein and peptide cations. Post ion/ion reaction spectra are consistent
with multiple modifications, where the number of modifications never exceeds the
number of reagents present in the initial cluster.

5.2

Experimental

5.2.1

Materials

Methanol was purchased from Mallinckrodt (Phillipsburg, NJ). FBMSA and
bovine

ubiquitin

were

purchased

from

Sigma-Aldrich

(St.

Louis,

MO).

KKKKKKKKKK (K10) was purchased from Pepnome Ltd. (Jida Zhuhai City,
Guangdong Province, China). Ubiquitin and K10 were prepared at a concentration of ~10
µM in a solution of 50/50 (v/v) water/methanol prior to positive nanoelectrospray
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ionization (nESI). The reagent anion, FBMSA, was prepared at a concentration of 1
mg/ml in a solution of water prior to negative nESI. The high concentration of the
reagent solutions aided in the formation of the cluster ions.

5.2.2

Mass Spectrometry

All experiments were performed on a QTRAP 4000 triple quadrupole/linear ion
trap mass spectrometer (AB SCIEX, Concord, ON, Canada), which has been modified to
perform ion/ion reactions.24 Alternately pulsed nESI emitters sequentially inject massselected anions and cations into the q2 reaction cell.25,26 Singly deprotonated FBMSA
cluster anions were first ionized and accumulated in the q2 reaction cell. Next, the
multiply charged cations were ionized and transferred to the q2 cell to undergo a mutual
storage reaction for 500-1000 milliseconds. Product ions resulting from the ion/ion
reaction were transferred to Q3 to perform MSn analyses and subsequent mass analysis
via mass-selective axial ejection (MSAE).27

5.3

5.3.1

Results and Discussion

FBMSA Reagent Cluster Anions

All previous ion/ion chemistry with FBDSA/FBMSA has been restricted to a
single derivatization per reaction. While multiple derivatizations have been achieved via
consecutive ion/ion reactions, each gas-phase reaction comes at the cost of one charge.
Therefore, the extent of modification is highly dependent on the initial charge of the
analyte ion. To circumvent such a restriction, a singly charged anion containing multiple
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reactive groups can be utilized to perform multiple covalent modifications within one
ion/ion encounter. FBMSA cluster anions form as [nRnNa-Na]-, where n represent a
number >2 and R represents the reagent FBMSA. The reagent FBMSA is utilized instead
of FBDSA due to the inability to form clusters with FBDSA. The sodium counter ions in
the cluster serve to stabilize the sulfonate moieties of FBMSA.

Negative mode

nanoelectrospray of the concentrated FBMSA solution generates singly deprotonated
reagent cluster anions containing various number of reagent molecules, i.e. the dimer
through the hexamer cluster (Figure 1).

5.3.2

Multi-Derivatized K10 Cations

Various reagent (i.e. di-, tri-, tetra, and penta) FBMSA cluster anions were
subjected to ion/ion reactions with triply protonated K10. As with FBDSA, the aldehyde
functionality of FBMSA undergoes nucleophilic attack by an unprotonated primary
amine upon collisional activation. The result of the rearrangement generates the loss of
H2O which is the signature of covalent modification. Figure 2 (a) displays the post
ion/ion reaction between [K10+3H]3+ and [2R2Na-Na]-. The dominant product ion is
[M+3H+2R2Na-Na-2H2O]2+, which is consistent with two covalent modifications. Here,
the degree of water loss never exceeds the number of reagent present in the cluster. Even
the neutral loss of an intact, sodiated reagent (-RNa) from the dimer adducted peptide
cation is consistent with the number of reactive reagents and water losses (i.e., one
reagent and one water loss).

It is noteworthy to mention that water loss is observed

without ion trap collisional activation. Collision-induced dissociation is necessary to
observed water loss following reactions that involve FBDSA anions. Water loss appears
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to occur spontaneously; however, energetic transfer conditions cannot be precluded as a
source of ion activation.
Ion/ion reactions involving the trimer, tetramer, and pentamer clusters exhibit
similar reaction behavior (Figure 2 (b), (c), (d) respectively). All demonstrate covalent
modification consistent with the highest number of reagents present within the cluster.
For instance, the pentamer FBMSA cluster generates [M+3H+5R5Na-Na-5H2O]2+, which
is consistent with five covalent modifications (Figure 2 (d)). The neutral losses from
[M+3H+5R5Na-Na-5H2O]2+ never exceed the possible number of covalent modification,
e.g. –(2H2O+2R2Na). These experiments demonstrate the ability to perform multiple gasphase covalent modifications in one ion/ion encounter via FBMSA-cluster reagent anions.

5.3.3

Multi-Derivatized Ubiquitin Cations

In order to view the applicability of this chemistry to larger systems, we
investigated reagent cluster chemistry with protein cations. Ubiquitin is a ~8.5 kDa
protein, which contains thirteen basic sites: the N-terminus, seven lysines, four arginines,
and one histidine residue. Based on this primary sequence information, there are eight
possible sites for covalent modification via the FBMSA-Schiff base chemistry.
[Ubiquitin + 7H]7+ was subjected to separate ion/ion reactions with singly deprotonated
FBMSA (i.e., [R-H]-) and [nRnNa-Na]- clusters, where n=2-5. In each case, the maximum
number of water loss from the ion/ion reaction complex was consistent with the number
of reagents present in the cluster. The product ion spectrum of the ion/ion reaction
between [Ubiquitin +7H]7+ and [5R5Na-Na]- is displayed in Figure 3(a). The ion/ion
reaction generates an intact complex (i.e., [Ubiquitin + 7H + 5R5Na - Na]6+) as well as
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nH2O losses, where n=1-4. Next, the ions present in the inset were subjected to isolation
and rapid sequential resonance excitation designed to sequentially activate each water
loss (i.e., higher m/z to lower m/z). The product ion spectrum following activation
generates a dominant -5H2O loss and various reagent neutral losses (Figure 3(b). The
five water loss is consistent with the highest number of covalent modifications with the
pentamer reagent anion. Similarly, for all of the other reagent clusters, the loss of n water
molecules was observed as the dominant number of water loss following sequential
activation. However, loss of water associated with the protein cannot be precluded as
water loss is a common process in peptide and protein activation. Sequential losses of
neutral FBMSA from the parent ion are also observed. Neutral loss of RH is observed
with four water losses as well as 2RH loss with three water losses. Here, the water loss
never exceeds the highest possible number of covalent modifications (e.g., -(4H2O+RH),
four potential modifications). Such an observation suggests that a fraction of the reagents
in the cluster engage in an electrostatic interaction, while the other fraction undergoes
covalent modification.
Collisional activation of [Ubiquitin + 6H]6+, [Ubiquitin + 7H + ]6+, and
[Ubiquitin +7H +55Na - Na]6+ are compared in Figure 4 and Figure 5, where 
represents covalent modification of the FBMSA reagent and the resulting dehydration.
Ion trap CID of [Ubiquitin + 7H + 55Na - Na]6+ generates a product ion spectrum
containing fragment ions that are derivatized multiple times, where two, three, and four
modifications are observed (Figure 4 (c)). For instance, b58 has up to four modifications
(4) with six lysine residues within the fragment ion. Also, y18 is observed in the
product ion spectrum, where only one lysine residue is present in the fragment ion. We
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note the neutral loss of RNa, which indicates that at least some of the water losses are not
related to covalent modification. However, the covalent modification of five sites cannot
be precluded.
In addition to reactions with the pentamer cluster, ubiquitin cations were
subjected to ion/ion reactions with the dimer, trimer, and tetramer cluster monoanions.
Ion trap CID was performed on [Ubiquitin + 7H +22Na - Na]6+, [Ubiquitin + 7H + 33Na
- Na]6+, [Ubiquitin + 7H + 44Na - Na]6+ (Figure 6). CID of multi-derivatized (i.e., dimer
through tetramer) ubiquitin cations exhibited similar dissociation behavior as the
[Ubiquitin +7H + 55Na - Na]6+.

In each case, the number of FBMSA-covalent

modifications never exceeded the number of primary amines within the fragment ion or
the number of reagent molecules present in the cluster.
In comparison to the unmodified, singly and doubly modified ubiquitin cations
(i.e., 0-2 ubiquitin), a few of the predominant dissociation channels are minimized in
the highly modified analog (i.e., 3-5 ubiquitin). Ion trap CID of [Ubiquitin + 6H]6+,
[Ubiquitin + 7H + ]6+, and [Ubiquitin + 7H + 2]6+ generates large contributions from
the y18 and b58 ions, while their contributions are minimized in the ion trap CID of
[Ubiquitin +7H +nnNa-Na]6+, where n= 3-5. In addition, the 3-5 ubiquitin dissociates
exclusively through aspartic acid cleavages with a drastic increase in the contribution
from b52/y24-ions (D52 G53 residues), while the 0-2 ubiquitin fragments through other
pathways (i.e., nonresidue specific and proline cleavages) in addition to the aspartic acid
pathways. Previous studies performing lysine guanidination of ubiquitin demonstrated
dominant fragmentation through aspartic acid cleavages.28 Guanidination lowers proton
mobilites, and as a result, inhibits proton catalyzed N-terminal proline and nonresidue-
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specific cleavages. At low proton mobilities, charge remote aspartic acid cleavages
dominate the fragmentation behavior. Similar dissociation behavior of multiply FBMSAmodified ubiquitin suggests an alteration of proton mobility.

5.4

Conclusions

Multiple covalent modifications within one ion/ion encounter have been
demonstrated on peptide and protein cations via FBMSA reagent cluster chemistry. The
reagent cluster anions are comprised of n number of FBMSA reagents and n-1 number of
counter sodium ions, generating an overall monoanion.

Cluster monoanions allows

multiple derivatizations at the cost of only one charge. FBMSA-clusters anions have
been formed as dimers, trimers, tetramers, and pentamers. Ion/ion reactions between
FBMSA-reagent cluster anions and triply protonated K10 have demonstrated up to five
covalent modifications. The number of covalent modifications never exceeds the total
number of reagents present in the cluster. Cluster chemistry was also applied to ubiquitin
cations. Upon reaction with FBMSA clusters, varying degree of water loss is observed.
Sequential ion trap CID can concentrate the number of water losses to the overall number
of reagents present in the cluster. Collisional activation of the multiply modified protein
cation generates fragment ions consistent with multiple covalent modifications.

Springer and the original publisher Journal of the American Society for Mass
Spectrometry, 24, 2013, 1045-1052, Boone M. Prentice, John R. Stutzman, Scott A.
McLuckey is given to the publication in which the material was originally published, by
adding; with kind permission from Springer Science and Business Media.
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Figure 5.1: nESI generated clusters of R, where R denotes FBMSA.
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Figure 5.2: Ion/ion reactions between [K10+3H]3+ and FBMSA reagent clusters, (a)
[2R2Na-Na]-, (b) [3R3Na-Na]-, [4R4Na-Na]-, [5R5Na-Na]-
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Figure 5.3: (a) Post ion/ion reaction spectrum of [Ubiquitin + 7H]7+ and [5R5Na-Na]-, (b)
Rapid sequential collisional activation over the isolated ion population in the insert of (a)
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Figure 5.4: Ion trap CID of (a) [Ubiquitin + 6H]6+ (b) [Ubiquitin + 7H + ]6+, (c)
[Ubiquitin + 7H + 5]6+
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Figure 5.5: Ladder structure of ubiquitin, (a) [Ubiquitin + 6H]6+ (b) [Ubiquitin + 7H +
]6+, (c) [Ubiquitin + 7H + 5]6+
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Figure 5.6 Ion trap CID of (a) [Ubiquitin + 7H + 2]6+ (b) [Ubiquitin + 7H + 3]6+, (c)
[Ubiquitin + 7H + 4]6+
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CHAPTER 6. CONVERSION OF MALDI-DERIVED PEPTIDE MONOANIONS
INTO MULTIPLY CHARGED CATIONS VIA GAS-PHASE ION/ION
REACTIONS

6.1

Introduction

Mass spectrometry (MS) has quickly developed into a powerful analytical tool for
the analysis of biological macromolecules (e.g., peptides, proteins, nucleic acids, and
lipids).1 Development of soft ionization techniques such as electrospray ionization (ESI)2
and matrix assisted laser desorption/ionization (MALDI)3,4 has afforded the introduction
of intact gaseous bio-ions into the mass spectrometer for structural and mass analysis.
Both of these ionization methods have developed separate niches in the field of MS.5 For
instance, ESI has been widely utilized in interfacing MS and liquid chromatography.
Ions generated via ESI tend to be multiply charged, which facilitates extensive
fragmentation and structural characterization of biological ions. The higher massed,
multiply charged ions enable (i.e., lower mass to charge ratio (m/z)) analysis within the
mass range of the MS (e.g., scannable RF amplitude applied to ion traps). Alternatively,
MALDI has been widely used on sampling surfaces such as imaging applications.
Ionization via MALDI generally produces lower charged ions than ESI, and for the most
part, MALDI generates singly charged ions. Activation of singly charged biological ions
often does not generate extensive fragmentation.6,7 In fact, the dissociation behavior is
generally dominated by low energy fragmentation pathways, e.g. C-terminal cleavage of
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an aspartic acid residue or N-terminal cleavage to a proline residue.8 The higher m/z of
ions (e.g.,>3,000 Th) can inhibit mass analysis and tandem MS processes, especially in
linear ion traps. Inadequacies generally arise from insufficient trapping conditions (i.e.,
shallow pseudo potential well) as well as the detectable mass range of the instrument
platform.
Ion/ion chemistry represents a unique area in the field of mass spectrometry that
can manipulate gas-phase ions with a high degree of control.9,10 Ion/ion chemistry has
demonstrated the ability to decouple the initial ion-type generated by the ionization
source from the ion-type ultimately subjected to tandem MS.11 This chemistry has been
utilized to manipulate analyte ion charge state,12,13 polarity,14,15,16,17 oxidation state (i.e.,
electron transfer),18,19 and covalently20,21,22,23 and/or electrostatically modify ions.17,24,25
These gas-phase reactions have many benefits: short reaction time (10-100s millisecnds),
high control of reactants, avoidance of complex reactions mixtures, ready comparison to
modified and unmodified analyte ion, etc.26 For instance, the process of charge inversion
affords ion formation in one polarity and analysis in the opposite polarity via multiple
proton transfer within a long-lived complex.27 Previous studies have investigated such a
process for various analytical reasons and applications.

These studies include the

fundamental studies of charge inversion reagents,16,17 charge inversion efficiency,14 and
increasing tandem MS performance on phosphopeptides. 28 However, all of these
examples have been restricted to analytes ions generated via ESI.
In this study, we demonstrate the gas-phase charge inversion of MALDI-derived
peptide monoanions into multiply charged cations so as to enhance tandem MS
performance and to afford analysis within the instrument detection range. Experiments
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are implemented via a dual-source interface attached to a hybrid triple-quadrupole/linear
ion trap tandem mass spectrometer.25,29 Here, the peptide monoanions are subjected to
ion/ion reactions with various protein reagent cations. Proteins ionized via ESI have a
propensity to generate highly charged ions; therefore, these ions are excellent candidates
for the charge inversion process. The charge inversion process proceeds via a long-lived
intermediate complex, comprised of the peptide anion and protein cation. The lifetime of
the long lived complex is sufficient to allow for multiple proton transfers,27 where
multiple factors contribute to the extent of proton transfer (i.e., gas-phase basicities,
charge state, and cross section). The products of the ion/ion reaction are charge reduced
protein cations and charge inverted peptide cations, as can be seen in process (1):14,16

[M-H]- +[R+nH]n+ → [M-H]----[R+nH]n+→ [M+yH]y+ + [R+(n-y)H](n-y)+

(1)

Ion/ion reactions have been performed on melittin (i.e., 26 amino acid peptide),
HDMNKLVL, and Chain B of insulin monanions. Multiple protein reagent cations have
also been utilized to optimize charge transfer: ubiquitin, myoglobin, carbonic anhydrase
(CA), and bovine serum albumin (BSA). In this study, we demonstrate two potential
applications for charge inverted MALDI monanions: enhance tandem MS performance
and analysis in the detection range.
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6.2

Experimental Section

6.2.1

Materials

Methanol, glacial acetic acid, and ammonium hydroxide were purchased from
Mallinckrodt (Phillipsburg, NJ).Ubiquitin from bovine erythrocytes, myoglobin, BSA,
carbonic anhydrase, insulin, melittin, cyctochrome c and 1,5-diaminonaphthalene (DAN),
tris (2-carboxyethyl) phosphine hydrochloride, and ammonium bicarbonate were
purchased from Sigma-Aldrich (St. Louis, MO). Synthetic peptides HDMNKLVL was
purchased from SynPep (Dublin, CA).

Peptides MQIFVK, TITLEVEPSDTIENVK,

EGIPPDQQR, LIFAGK, TLSDYNIQK, and ESTLHLVLR were generated from a tryptic
digestion of ubiquitin.

6.2.2
The

MALDI

matrix,

DAN,

Methods
was

prepared

in

69.5/29.5/1

water/acetonitrile/ammonium hydroxide at a concentration of 10 mg/mL.

(v/v)
Peptide

analytes were prepared in a ~100 µM aqueous solution prior to a 50/50 (v/v) mixture with
the MALDI matrix solution. 2.0 µL of the matrix/analyte solution was spotted onto the
MALDI stage plate and allowed to air-dry prior to attachment to the AP-MALDI source.
The protein reagents were composed of a ~100 µM solution of 49.5/49.5/1 (v/v/v)
water/methanol/acetic acid for positive microionspray.
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6.2.3

Disulfide Reduction

The procedure for disulfide reduction has been described previously. Reduced
insulin was filtered through a disposable PD-10 desalting column (GE Healthcare) using
a 1% acetic acid buffer solution. Collected fractions were lyophilized and dissolved in
250 µL of water.30

6.2.4

Mass Spectrometry

Experiments were performed on a 4000 AB Sciex QTRAP (Concord, ON,
Canada), which has been modified to perform ion/ion reactions. 31 The ion source is
equipped with an AP-MALDI source (MassTech, Columbia, MD) and with a
microionspray emitter (New Objective Inc, Waburn, MA) orthogonal to the sample inlet
(Figure 1).25,29,32 The microionspray emitter, remote to the MS inlet and MALDI stage
plate, allows for the introduction of opposite polarity ions into the MS. Briefly, the APMALDI source has a circular opening, where a conductive transfer tube penetrates into
the ion source and attaches to the curtain plate. The microionspray is directed towards
the transfer tube and upon ionization/nebulization, ions travel into the transfer tube and
the ion source.
The protein reagent cations were generated via microionspray at a continuous
flow rate of 8.0 µL/min from a silica sprayer (364 µm outer dimension, 48 µm inner
dimension, Polymicro Technologies, Phoenix, AZ). Nitrogen acts as the nebulizing gas,
which helps guide the reagent anions into the ion source. The nebulizing gas was
triggered/pulsed via MS Expo software (AB Sciex, Concord, ON, Canada) during
positive ion injection conditions. Once protein cations entered the MS, the ions were
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transferred to the q0 cell and cooled to help remove neutral adducts. Following trapping,
protein cations were then transferred to q2 and stored prior to a mutual storage
reaction.33,34 Peptides, individually spotted in DAN, were ablated via a 337-nm, 10Hz
nitrogen laser (AP-MALDI Ion Source 110, MassTech, Columbia, MD) and transferred
to the q2 collision cell to undergo ion/ion reactions with the reagent anions. Product ions
generated in q2 were transferred to Q3 for further collisional activation and subsequent
mass analysis.35

6.3

Results and Discussion

Singly deprotonated melittin anions were subjected to charge inversion ion/ion
reactions with various protein reagent cations (i.e., ubiquitin, cytochrome c, carbonic
anhydrase, and bovine serum albumin (BSA)) to ultimately generate multiply protonated
analyte ions.

Ion/ion reactions of singly deprotonated anions and multiply protonated

cations proceed via two distinct proton transfer channels: charge transfer within a longlived complex or a proton hopping mechanism. The first process generates the charge
inverted peptide ions via transfer of two or more protons prior to dissociation of the
complex. The second process occurs at sufficiently long distances, where the relatively
high electric fields associated with the oppositely charged ions facilitate a single proton
transfer. This process ultimately neutralizes the monoanion analyte. Charge inverted
products resulting from two or more successive proton transfer reactions are highly
unfavorable due to the low absolute number of the neutral analyte and low ion number
densities in the ion trap.14,16,27
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6.3.1

Optimal Protein Reagent Cations

Initial experiments were devoted to determining an optimal protein reagent cation
to maximize the number of protons transferred to the analyte anions; therefore, singly
deprotonated melittin (Figure 2(a)) was subjected to charge inversion ion/ion reactions
with various multiply protonated reagent cations.

Melittin is a 2.9 kDa peptide,

containing six basic sites (e.g., N-terminus, lysine), where the presence of multiple basic
sites will facilitate multiple proton transfer (Figure 2). Melittin was also selected as an
initial analyte anion since the singly deprotonated form falls within 50 m/z of the upper
limit of the instrument mass range. Mass analysis of melittin anions allows for the
optimization of instrument conditions prior to the ion/ion chemistry with analyte ions
outside of the mass range. Ubiquitin cations were used initially to establish a baseline
with a small and low-charged protein (Figure 3(a)). The charge state utilized for reaction
was selected on the highest charge state that produced abundant signal upon a RF/DC
isolation in Q1. Figure 4(a) illustrates the post ion/ion product ion spectrum of [MelittinH]- and [Ubiquitin +8H]8+. The reaction results in the conversion of singly deprotonated
melittin into doubly and triply charged melittin (i.e., [M+2H]2+ and [M+3H]3+), while the
singly protonated form is not observed. In addition to proton transfer, attachment of
melittin to the reagent cation, [M+R+5H]5+, is observed, where M and R are
representative of the analyte and reagent, respectively.
Previous studies involving ion/ion charge inversion have demonstrated multiple
factors that influence charge partitioning upon dissociation of the long lived complex: the
overall number of basic sites, their gas-phase basicities, reagent charge state, and the
electrostatic repulsion present within the long-lived complex. In the case of gas-phase
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basicity, charge transfer continues to occur as long as the gas-phase basicity (GB) of the
analyte exceeds that of the reagent as it loses charge. However, the GB of the analyte
and reagent can be altered by coulomb repulsion within the complex.16 In addition,
smaller reagent cross sections (with the same amount of charge) increase the electrostatic
repulsion within the long-lived complex, which tends to favor increased charge transfer
so as to minimize repulsion. Larger protein cations tend to minimize repulsion due the
possibility of many intermolecular interactions (e.g., hydrogen bonding, dipole-dipole).
Higher charge densities are also expected to lead greater charger transfer (i.e., lower GB
and greater repulsion); however, significantly high charge densities have diminishing
effects.14 At very high charge states, the proton hopping mechanism is preferred due to
the potential energy of the opposite polarity ions being equal to the reaction energy at
longer distances.14,16,27 Ultimately, a reagent cation with a low GB, small cross section,
high degree of repulsion, and high charge state would be optimal.
Following ubiquitin, a larger and higher charged myoglobin protein was utilized
as a protein reagent cation (Figure 3(b)). In order to achieve higher charge with our
ionization platform, a larger cross sectioned reagent must be utilized, assuming that
higher massed, higher charged proteins own a larger cross section. Myoglobin has a
molecular mass near 14 kDa with a charge state distribution ranging from 8+ to 16+ upon
ionization, while ubiquitin has a mass near 8.5kDa with a charge state distribution
ranging from 4+ to 9+. Ion/ion reactions were performed between singly deprotonated
melittin and [myoglobin+16H]16+ (Figure 5(a)). Melittin monoanions are converted to
doubly and triply protonated melittin in a 1:1 ratio as similarly observed with the
ubiquitin reagent cations. The similar charge inversion behavior can be attributed to
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similar GBs of [myoglobin+16H]16+ and [ubiquitin+8H]8+, i.e. 210 kcal/mol (crude linear
extrapolations from Williams et al).36 The charge states of all the protein reagent cations
utilized in the ion/ion reaction are considerably lower in overall charge than cations
generated by ESI. This observation can be attributed to the dual injection interface,
which ionizes the proteins remote to the aperture and likely introduces charge reduction
processes prior to introduction in the MS. Utilizing these lower charges, and in turn
higher GBs, diminishes the degree of charge transfer since the analyte exceeds the
reagents GBs more rapidly upon each charge transfer. In addition, the product ion
spectrum also displays evidence of single proton transfer (i.e.,[myoglobin+15H]15+) as
well

as

consecutive

ion/ion

reactions

(i.e.,

[myoglobin+12H]12+

though

[myoglobin+7H]7+) as more than four transferred protons are not observed.
In an attempt to utilized a protein cation with more charge and a lower GB,
melittin monoanions were subjected to ion/ion reactions with [CA+23H]23+ (Figure 5(b)).
Carbonic anhydrase is a 29 kDa protein with a charge state distribution from 13+ to 24+
(Figure 3(c)). A crude linear extraction of the GB of CA from Williams et al36 generates
a value of 200 kcal/mol at +23. The product ion spectrum between melittin monoanions
and CA polycations generates doubly and triply charged melittin in a 3:2 ratio,
respectively. The slight decrease in GB does not generate a higher degree of charge
transfer, i.e., [M+4H]4+; however, there is a decrease in the relative abundance of triply
protonated melittin. This observation may be attributed to the larger cross section of CA
than ubiquitin and myoglobin cations, which favors less charge transfer due to the lower
coulomb repulsion between melittin and CA ions.16 To extend the range of observation,
BSA reagent cations (i.e., [BSA+40H]40+) were subjected to ion/ion reactions with
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melittin monoanions.

BSA is a 66.5 kDa protein which generates a charge state

distribution over 26+ to 42+ (Figure 3(d)). BSA was utilized due the ability to generate
higher charge than the other protein reagent cations; however, upon further investigation,
the GB of [BSA+40H]40+ is approximately 205 kcal/ mol.36 Therefore, it is expected that
similar charge states of melittin will be generated following the ion/ion reaction. Figure
5(c) illustrates the post ion/ion reaction, where the triply and doubly protonated melittin
are observed in a ratio of 3:1, respectively. Reaction with BSA cations generates the
highest degree of [melittin+3H]3+ compared to the other protein reagent cations. A likely
explanation is that the extrapolated GB of BSA is incorrect and the true GB is lower.
With a possible lower GB and higher degree of charge compared to the other protein
reagent cations, a higher degree of charge separation would be expected.

6.3.2

Conversion of Peptide Anions Outside of the Native Mass Range

After optimizing the instrument conditions and ion/ion chemistry, this chemistry
was applied to MALDI-derived analyte monoanions that fall outside of the mass
spectrometer’s mass range (in our case 2900 m/z).

Insulin chain B is 3.4 kDa peptide

(FVNQHLCGSHLVEALYLVCG ERGFFYTPKA) that is generated via solution phase
disulfide reduction of insulin. Ionization of chain B via MALDI generates a mass
spectrum void of any analyte signal due to fact that [Chain B-H]- falls outside of the
detection range (~500 m/z) (Figure 6(a)). Singly deprotonated chain B is likely reaching
the Q3 linear ion trap but is not detected due to the instrument constraints (i.e., necessary
RF amplitude to perform mass selective axial ejection is not achieved). Hence, insulin
chain B was subjected to ion/ion reactions with BSA reagent protein cations to
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demonstrate the ability to lower the m/z quotient of the gas-phase ions so as to facilitate
detection of the analyte ions. Chain B contains five basic sites (e.g., histidine, arginine),
and since this nears the number of melittin basic sites, it is expected that chain B will
undergo a similar extent of charge transfer (unless their respective GBs are vastly
different). The product ion spectrum of the ion/ion reaction between [Chain B-H]- and
[BSA+36H]36+ is illustrated in Figure 6(b). Singly deprotonated chain B is converted to
doubly and triply protonated Chain B. The transfer of multiple protons to chain B
modifies the m/z ratio (i.e., lowering the quotient), thus facilitating analysis within the
detection range. Such an observation suggests that chain B monoanions are at least
reaching the q2 cell to undergo ion/ion reactions. This conversion chemistry is practical
in situations where a MALDI ionization source is coupled to a trapping analyzer that is
not equipped with a sufficient mass detection range.

6.3.3

Increasing Structural Characterization upon Charge Inversion

Singly charged ions, whether cations or anions, often will not fragment
extensively.6,7 As mentioned previously, ionization via MALDI has a propensity to
generate singly charged ions in both the negative and positive ion mode. The conversion
chemistry demonstrated in this study can be utilized to increase structural information as
multiply charged ions tend to generate a higher degree of primary information. Singly
deprotonated HDMNKVLDL was subjected to ion/ion with [cyctochrome c +12H]12+ so
as to highlight the dissociation behavior of each charge state (Figure 7). Following the
ion/ion reaction, [HDMNKVLDL-H]- is converted to the singly and doubly protonated
forms (Figure 7(a)). Ion trap collision induced dissociation (CID) of [M+2H]2+ generates
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a product spectrum with extensive fragmentation (Figure 7(b)), where seven y-ions and
seven b-ions are generated. The fragmentation behavior also exhibits uniformity even in
the presence of two aspartic acid residues. Collisional activation of the singly protonated
peptide generates a product ion spectrum with limited fragment ions (i.e, four y-ions and
five b-ions). Here, the singly protonated peptide can be envisioned as a product of
positive ionization mode MALDI. Fragmentation is also dominated by the aspartic acid
low energy CID pathway, a selective cleavage well known to be a more dominant and
facile cleavage in peptide monocation fragmentation than most other fragmentation
processes.8 This simple comparison displays the utility of this conversion chemistry, i.e.
the ability to generate and dissociate multiply charge cations compared to singly charged
ions that MALDI generates upon ionization. While there is not a comparison to the
monoanion, it is well documented that peptide cations yield significantly more
information than peptide anions (i.e., dominated by neutral losses).

6.4

Conclusions

This study demonstrates the gas-phase charge inversion of peptide monoanions into
multiply charged cations via ion/ion reactions. The charge inversion process proceeds
via a long-lived intermediate complex, comprised of the reagent and analyte ions, where
multiple protons are transferred within the complex. Different protein reagent cations (i.e.
varying cross section, charge, and gas-phase basicity) have been investigated to optimize
the degree of charge transfer from the reagent to the analyte. All of the protein reagent
cations are suitable reagents as each transferred up to four protons; however, BSA cations
generated the highest relative abundance of four proton transfer products. Conversion
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chemistry displays a distribution of charge transfer, which can be attributed to the
competition between various dissociation channels of the long-lived complexes. This
study also demonstrates two potential applications for MALDI-derived ions: (1) lowering
the m/z ratio of the analyte ion to facilitate detection and (2) increasing sequence
coverage upon dissociation. The first application has been demonstrated on insulin chain
B, where conversion from a singly charged ion into a multiply charged ion afforded
detection.

Collisional activation of charge inversion product ions also exhibited an

increase in fragmentation of peptide dications compared to singly protonated peptide
cations.

Reprinted (adapted) with permission from Stutzman, J. R.; Blanksby, S. J.; McLuckey,
S.A. Anal. Chem. 2013, 85, 4713-4720. Copyright (2013) American Chemical Society.
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Figure 6.1: Modified AP-MALDI source, attached to a QTRAP 4000, capable of
multisource injection.
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Figure 6.2: Negative ionization mode of melittin via AP-MALDI, M is equivalent to
GIGAVLKVLTTGLPALISWIKRKRQQ-NH2.
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Figure 6.3: Positive mode microionspray ionization of a) ubiquitin, b) myoglobin, c)
carbonic anhydrase, d) bovine serum albumin. The red color represents the isolated
protein cation subjected to ion/ion reactions.
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Figure 6.4: Product ion spectrum following the ion/ion reaction between [Melittin-H]and [Ubiquitin+8H]8+. M is representative of melittin, while the R+ is equivalent to the
charge state of ubiquitin.
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Figure 6.5: Product ion spectrum following the ion/ion reaction between [melittin-H]- and
a) [myoglobin+16H]16+, b) [carbonic anhydrase+23H]23+, c) [BSA+39H]39+ , M is
representative of melittin, while the red numbers represent the isolated precursor reagent
cation.
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Figure 6.6: a) Negative ionization mode of chain B via AP-MALDI, b) ion/ion reaction
and
[BSA+36H]36+,
M
is
equivalent
to
between
[Chain+B-H]FVNQHLCGSHLVEALYLVCG ERGFFYTPKA.
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Figure 6.7: a) ion/ion reaction between [M-H]- and [cytochrome c+ 12H]12+, b) Ion trap
CID of [M+2H]2+, c) Ion trap CID of [M+H]+, M is equivalent to HDMNKVLDL.
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CHAPTER 7. GAS-PHASE TRANSFORMATION OF PHOSPHATIDYLCHOLINE
CATIONS TO STRUCTURALLY INFORMATIVE ANIONS VIA ION/ION
CHEMISTRY

7.1

Introduction

Mass spectrometry (MS) has become an essential analytical tool for the
identification and structural characterization of biological macromolecules.1,2,3 In tandem
MS (MS/MS or MSn), the polarity in which the analyte ion is most efficiently formed
does not always provide sufficient structural information upon collision-induced
dissociation (CID).

For instance, phosphatidylcholines (PC), a subclass of

glycerophospholipids, are efficiently ionized in the positive polarity, but their cationic
versions generate limited structural information upon CID. PCs compose thirty percent
of cell membranes in mammalian cells 4 and can act as secondary messengers in
metabolic signaling/pathways.5 PCs are composed of a glycerol backbone with two fatty
acid chains attached at the sn-1 and sn-2 positions while a phosphocholine moiety is
attached at the sn-3 position. Due to the presence of a fixed positive charge quaternary
amine, PCs readily generate gas-phase cations in positive ion mode electrospray
ionization (ESI). 6 However, collisional activation of PC cations generally yields the
phosphocholine moiety (184 m/z) as the dominant and often exclusive product. The
phosphocholine fragment ion provides insight on only the phospholipid class and does
not provide structural information about the individual acyl chains.7,8 Elucidating the
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composition of the individual fatty acid chains is important due to the diverse physical
properties of PCs (i.e., the number of carbons and extent of unsaturation) as these
properties relate to their lipid biochemistry. 9,10,11

With the presence of the choline

moiety, PCs cannot be ionized in the negative polarity by deprotonation6 and therefore
structural information of the individual fatty acid chains cannot be easily accessed
without solution phase additives (see below).

Traditionally this might have been

addressed by gas chromatographic analysis of the hydrolyzed and derivatized fatty acids
arising from the PC fraction of the lipid extract, but this process results in a pooling of all
fatty acids and a loss of molecular information.12
Efforts to better characterize PCs by tandem MS have included CID studies of
adducted PCs in both the positive13 and negative ion modes.8,14,15,16 Gas-phase lithium
adducts of PCs generated by positive ESI of solution phase PC mixtures have shown
neutral losses of lithiated fatty acid chains (i.e., RCO2Li, where R is the alkyl chain) upon
CID. The difference in m/z between the product and precursor ion corresponds to the
degree of unsaturation and chain length. However, the structurally informative peaks
were of low relative abundance and the spectra were complicated by additional neutral
losses.13 In the negative ion mode approach, millimolar concentrations of salts were
added to a PC solution to produce gas-phase adducted PC anions (e.g., [PC+Cl]- and
[PC+CH3CO2]-). Collisional activation of the adducted PC anions produced a neutral
loss comprised of the counter anion and a methyl cation from the quaternary ammonium
(i.e., CH3Cl and CH3CO2CH3), yielding [PC-CH3]-.

Subsequent CID of [PC-CH3]-

generated fatty acid carboxylate anions (RCO2-) and neutral losses associated with free
acids (RCO2H) or ketene derivatives (RCHCO), which are all indicative of the
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composition of the individual fatty acid chains.8,14-16 In both of the solution phase
methods, the high salt concentrations can lead to poor ionization efficiency, spectral
complexity upon ionization, and incompatibilities with liquid chromatography (LC)
solvent systems.
The type of ion subjected to tandem MS is usually determined by the ionization
method and conditions. An alternative approach is to transform in the gas-phase an iontype that is readily generated by an ionization method to another ion-type that more
readily yields structural information of interest, preferably mass-selection. Gas-phase
ion/ion reactions have been shown to be particularly useful for many ion
transformations,17,18 particularly when conducted within the context of MSn, whereby the
analyte and reagent ions are each mass-selected prior to reaction. The use of ion/ion
reactions within the context of an MSn experiment allows the definition of the ion-type to
be de-coupled from the initial ionization conditions.19 As a result, the ion-type subjected
to activation can be independently optimized to generate the most informative
fragmentation. Ion/ion reactions have been utilized in acid/base reactions (i.e., proton
transfer),

20 , 21

reduction/oxidation reactions (i.e., electron transfer),

covalent 24 , 25 , 26 , 27 and/or electrostatic modification. 28 , 29

22 , 23

and

Previous studies have

demonstrated the significance of ion-type transformation and its relation to increased
sequence coverage. 30 , 31 , 32 For instance, MALDI-derived tryptic peptide monocations
covalently and electrostatically modified with benzene disulfonic acid dianions via
ion/ion reactions demonstrated increased sequence coverage upon collisional activation,
especially in the form of b-type ions.33
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In the case of PC ions, an example of gas-phase ion-type transformation via
ion/ion chemistry has been demonstrated in the electron transfer dissociation (ETD) of
doubly sodiated PC cations, [PC+2Na]2+ using azobenzene radical anions as the ETD
reagent. ETD induced cleavages at each ester linkage (i.e., neutral loss of a fatty acid
chain) with additional neutral loss of the quaternary nitrogen moiety. CID of the charged
reduced electron transfer product that did not undergo dissociation (i.e., the ETnoD ion),
[M+2Na]+•, generated results similar to the electron transfer reaction. Similar to the
lithiated PC cation study, this method provided information on the number of carbons and
the degree of unsaturation for each fatty acid chain via neutral losses.34
In this study, we demonstrate the gas phase transformation of PC monocations
into demethylated PC anions (i.e., [PC-CH3]-) via ion/ion reactions, where pre- and posttransformation structural characterization is compared. PC monocations are subjected to
ion/ion reactions with doubly deprotonated 1,4-phenylenedipropionic acid (PDPA). The
product of the ion/ion reaction is a negatively charged complex, comprised of PDPA and
PC, i.e. [PC+PDPA-H]-. Collisional activation of the complex generates [PC-CH3]- as
seen in process (1):

[PC+H]+ + [PDPA-2H]2-  [PC+PDPA-H]- [PC-CH3]- + [PDPA+CH3+H]

(1)

Gas-phase ion/ion reactions have been performed on synthetic PC isomers, 1-palmitoyl2-oleoyl-sn-glycero-3-phosphocholine (16:0/18:1 PC) and 1-oleoyl-2-palmitoyl-snglycero-3-phosphocholine (18:1/16:0 PC). Collisional activation of [PC-CH3]- generates
large relative contributions from fatty acid carboxylate anions (RCO2-) and less abundant
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neutral losses of fatty acids (RCO2H) and ketene derivatives (RCHCO), whereas
collisional activation of [PC+H]+ produces exclusively the phosphocholine cation.
Transformation of PC monocations via ion/ion reactions facilitates the production of
structurally informative anions and the identification of fatty acid composition without
recourse to solution phase salt additives.

7.2

Experimental

7.2.1

Materials

Methanol, chloroform, and ammonium hydroxide were purchased from
Mallinckrodt (Phillipsburg, NJ). Acetonitrile and 1,4-phenylenedipropionic acid were
purchased from Sigma-Aldrich (St. Louis, MO).

1-palmitoyl-2-oleoyl-sn-glycero-3-

phosphocholine and 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine were purchased
from Avanti Polar Lipids, Inc (Alabaster, AL).

PC analytes were prepared at a

concentration of ~30 µM in a solution of 50/50 (v/v) chloroform/methanol prior to
positive nanoelectrospray ionization (nESI). The reagent anion, PDPA, was prepared at a
concentration

of

~

220

µM

in

a

solution

of

49.5/49.5/1

(v/v/v)

acetonitrile/methanol/ammonium hydroxide prior to negative nESI.

7.2.2

Solution Phase PDPA Spiking

A solution mixture of PC (i.e., PC16:0/18:1 or PC18:1/16:0) and PDPA was prepared at
concentrations of 10 µM and 140 µM, respectively. The solution was subjected to
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negative mode nESI, where MSn analyses and subsequent mass analysis were performed
in Q3.

7.2.3

Mass Spectrometry

All experiments were performed on a QTRAP 4000 triple quadrupole/linear ion
trap mass spectrometer (AB SCIEX, Concord, ON, Canada), which has been modified to
perform ion/ion reactions.35 Alternately pulsed nESI emitters sequentially inject massselected anions and cations into the q2 reaction cell.36,37 Doubly deprotonated PDPA
anions were first ionized and accumulated in the q2 reaction cell. Next, the singly
charged PC cations were ionized and transferred to the q2 cell to undergo a mutual
storage reaction for 1000 milliseconds.

Following accumulation of the doubly

deprotonated PDPA anions and throughout the ion/ion reaction period in the
transformation efficiency study, any singly charged PDPA anions that were formed from
ion/molecule reactions due to adventitious basic vapors or ion/ion reactions were
subjected to continuous resonance ejection to minimize the possibility of singly charged
anions reacting with the singly charged cations. Product anions resulting from the ion/ion
reaction were transferred to Q3 to perform MSn analyses and subsequent mass analysis
via mass-selective axial ejection (MSAE).38
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7.3

7.3.1

Results and Discussion

Transformation of PC Cations

Two PC isomers, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0/18:1
PC) and 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1/16:0 PC), have been
subjected to ion/ion reactions with doubly deprotonated PDPA. The ion/ion reaction
produces a negatively charged complex (i.e., [PC+PDPA-H]-), which is stabilized by a
strong electrostatic interaction between the fixed charge quaternary ammonium group of
PC and a carboxylate of PDPA (Scheme 1).25 Figure 1(a) illustrates the product ion
spectrum following an ion/ion reaction between [PDPA-2H]2- anions and [PC16:0/18:1+H]+
cations. The post ion/ion reaction spectrum displays product ions corresponding to
[PC16:0/18:1+PDPA-H]- and a charge reduced reagent anion (i.e., [PDPA-H]-). Proton
transfer to the reagent dianion can occur via two pathways: a fly-by mechanism or
charge transfer upon separation of the long-lived complex.39
Subsequent isolation and collisional activation of the long-lived complex,
[PC16:0/18:1+PDPA-H]-, produces a highly abundant [PC16:0/18:1-CH3]- ion along with
consecutive fragments consistent with charged and neutral losses of the fatty acid chains
(Figure 1(b)). Observation of the demethylated PC anions indicates methyl cation and
proton transfers to the anionic reagent within dissociation of the complex, thus producing
a neutralized PDPA reagent (see Scheme 1). The observation of [PC-CH3]- mirrors the
results of solution phase acetate and chloride salt experiments, where collisional
activation of [PC+CH3CO2H]- or [PC+Cl]- generated a demethylated PC anion.8,14-16
Gas-phase methyl cation transfer between carboxylates and quaternary ammonium
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groups has been observed previously within the context of an ion/ion reaction.27 Alkyl
(i.e., ethyl, propyl, butyl, isobutyl) cation transfer has also been observed upon CID of
ESI-generated complexes composed of sulfophenyl benzoic acid dianions and
tetraalkylammonium monocations. 40 Collisional activation of the gas-phase anionic
complex produced either proton or alkyl cation transfer to the sulfophenyl benzoic acid
dianions, as similarly seen in this work with collisional activation of PDPA-adducted PCs.
The low relative abundance of the proton transfer product (i.e., [PDPA-H]-) in the
dissociation spectrum is particularly noteworthy (Figure 1(b)). This low contribution of
[PDPA-H]- compared to [PC16:0/18:1-CH3]- suggests that transfer of a proton and methyl
cation upon collisional activation is a dominant pathway, while sole proton transfer
without methyl cation transfer is a less favorable pathway.

The other PC isomer,

18:1/16:0 PC, yields similar results to the 16:0/18:1 compound for both the ion/ion
reaction and subsequent collisional activation of the long-lived complex (Figure 2).
The analytical utility of the gas-phase transformation of PC cations to
demethylated PC anions is dependent upon the value of the information gained from
changing one ion-type to another, as discussed below, as well as the reaction efficiency.
A lower limit to the efficiency of converting PC16:0/18:1 cations to the anion complex
[PC16:0/18:1-CH3]- can be derived from the spectrum of Figure 1(a) from the ratio [PDPAH]-/([PDPA-H]-+[PC16:0/18:1-CH3]-). This yields an efficiency of roughly 25%. However,
a significant fraction of the observed [PDPA-H]- signal in Figure 1(a) arises from
ion/molecule proton transfer from polar vapors present in the vacuum system.
Furthermore, the accumulation of [PDPA-H]- due to ion/ion and ion/molecule reactions
leads to an increase in the neutralization of the PC cations from ion/ion reactions with the
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[PDPA-H]- anions.

We therefore chose to measure an “operational” efficiency of

transforming PC16:0/18:1 cations to demethylated PC anions, which is defined as:41,42

Transformation Efficiency % 

([ PC  CH 3  H ])  (ConFragments )
 100
 PCi   PCf

where Σ[PC-CH3-H] is the abundance of demethylated PC anions produced upon CID of
the long-lived complex ([PC+PDPA-H]-), Σ(ConFragments) is the abundance of
consecutive fragments from [PC-CH3]- following CID of the long-lived complex, ΣPCi is
the abundance of [PC+H]+ after isolation and before ion/ion transformation, and ΣPCf is
the abundance of residual [PC+H]+ after transformation. A resonance ejection voltage
was applied throughout the reaction period to eject [PDPA-H]- ions generated by ion/ion
and ion/molecule reactions to minimize any neutralization of the PC cations associated
with ion/ion reactions with [PDPA-H]-. By subtracting PCi from PCf, the transformation
efficiency is limited to the fraction of [PC+H]+ that undergoes an ion/ion reaction with
[PDPA-2H]2-.

The transformation efficiency determined in this way represents the

maximum possible efficiency for conversion of [PC+H]+ to [PC-CH3]- because it
represents the value that would be obtained if all reactant cations undergo an ion/ion
reaction. Complete depletion of analyte ions is achievable provided there is an excess of
reagent ions, there is good overlap in the ion populations, and the reaction time is
sufficient to allow for the reaction to go to completion. It is also emphasized here that the
measurement yields an “operational” efficiency rather than an absolute efficiency due to
possible differences in detection efficiencies for positive ions and negative ions. The
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absolute values for voltages applied to the conversion dynode and multiplier were the
same in both detection polarities with the only difference being the polarity of the
conversion dynode.

In this study, the transformation efficiency of PC cations to

demethylated PC anions was measured to be 49 + 7%. The major loss process is
expected to be neutralization of the cation by [PDPA-2H]2- as there are no major
competing charge inversion channels and little resonance ejection of the [PC+PDPA-H]complex is expected under the collisional activation conditions used to dissociate it.
Overall, the results demonstrate that the ion/ion charge inversion/CID process used to
generate the [PC-CH3]- ions is clearly efficient enough for analytical use.

7.3.2

MS/MS of [PC-CH3]- Anions

Ion trap CID of 16:0/18:1 PC prior to and after ion/ion transformation (i.e.,
[PC16:0/18:1+H]+ and [PC16:0/18:1-CH3]-) are compared in Figure 3. Collisional activation of
[PC16:0/18:1-CH3]- produces a structurally informative product ion spectrum, where loss of
neutral and charged fatty acid chains are observed (Figure 3(a)). These fragment ions
allow for the determination of chain length and the degree of unsaturation. The most
favorable dissociation pathway appears to be the generation of a charged fatty acid chain
from the sn-1 or sn-2 position, i.e., [C16H31CH2COO-H]- and [C14H29CH2COO-H]-.
Neutral losses of fatty acids as ketenes (e.g., [PC16:0/18:1-CH3-C14H29CH=C=O-H]-) and
free fatty acids (e.g., [PC16:0/18:1-CH3-C14H29CH2COOH-H]-) are also observed in low
abundance. Similar dissociation behavior of demethylated PC anions8,14-16 and other
glycerophospholipids43,44,45,46 has been noted previously in the literature. In contrast, CID
of the [PC16:0/18:1+H]+ ion yields the phosphocholine cation as the strongly dominant

167
product (Figure 3(b)). Figure 3(c) depicts the relationship between bond cleavage and
product ion-type (e.g., cleavage of the ester bond leads to charged or neutral loss of a
single fatty acid chain). In addition, a comparison of sn-cleavage position reveals a larger
contribution from ions produced from the cleavage at the sn-2 position (i.e.,
[C16H31CH2COO-H]-

and [PC16:0/18:1-CH3-C16H31CH=C=O-H]-) compared to those

produced from cleavage at the sn-1 position (i.e., [C14H29CH2COO-H]- and [PC16:0/18:1CH3-C14H29CH=C=O-H]-). Ekroos et al. noted the relative favorability of sn-2 cleavage
in synthetic PC isomers and biological samples;14 however, structural characterization via
relative abundance comparisons can be misleading due to the likely isomeric mixtures
present in synthetic and natural samples. Additionally, relative abundance ratios of the
sn-1 and sn-2 position were previously demonstrated to be dependent on fatty acid chain
length and degree of saturation, thus suggesting caution in assigning exact structures.47
Figure 4(a) depicts the product ion spectrum following ion trap CID of [PC18:1/16:0CH3]-. Collisional activation of [PC18:1/16:0-CH3]- produces similar fragment ions to the
16:0/18:1 PC isomer, (i.e., neutral losses of fatty acid ketenes, free fatty acids, and
charged fatty acids), thus providing a diagnostic fragmentation spectrum. As seen with
the 16:0/18:1 PC (Figure 3(a)), the dissociation behavior of 18:1/16:0 is dominated by the
production of fatty acid anions (Figure 4(a)). However, the most significant difference
between the two isomers (i.e., between 16:0/18:1 PC and 18:1/16:0 PC) is the reversal of
the relative abundances of the [C14H29CH2COO-H]-/ [C16H31CH2COO-H]- and [PC-CH3C14H29CH=C=O-H]-/[PC-CH3-C16H31CH=C=O-H]- ions. This reversal in intensity may
be attributed to the position of the fatty acid chain (i.e., sn-1 or sn-2), where cleavage of
sn-2 appears to be more favorable. Ekroos et al. reported a similar change in relative
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abundances between isomeric demethylated PC anions.14

Collisional activation of

[PC18:1/16:0+H]+ is depicted in Figure 4(b). Ion trap CID of the PC cation produces a
dominant phosphocholine moiety, as also seen with 16:0/18:1 PC (Figure 3(b)). While
caution should be exercised in the interpretation of these ion abundances, the fact that
these low abundant spectral features can be detected following charge inversion presents
a significant advantage over analysis in the positive ion mode alone.

7.4

Solution Phase PDPA Mixture

The preceding results demonstrate the formation of a [PC+PDPA-H]- complex,
which dissociates to the [PC-CH3]- ion that can yield structurally informative products
upon CID in the gas-phase. We also sought to generate such a complex directly from
solution for two reasons. First, generation of the complex directly from solution would
enable access to the precursor ion of interest without recourse to gas-phase ion/ion
reactions, in analogy with the work of Ekroos et al.14 Of course, such an approach might
also require a separate positive ion experiment to confirm the phospholipid class
information. Second, we were interested to see if a complex formed in solution would
differ in its CID behavior from that of the complex formed via ion/ion reaction. Direct
ionization of a solution phase mixture containing PDPA and 16:0/18:1 PC via negative
mode nESI is illustrated in Figure 5(a).

Ionization of the mixture produces low

abundance PDPA-adducted PC anions (i.e., [PC16:0/18:1+PDPA-H]-) among dimers of
PDPA and substantial chemical noise. Collisional activation of the complex produces the
demethylated PC anion (data not shown). Ion trap CID of the demethylated PC anion
(Figure 5(b)) generates similar dissociation behavior compared to the analogous
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[PC16:0/18:1-CH3]- produced via ion/ion reactions (Figure 3(a)).

The solution phase

method clearly exhibits spectral complexity as well as limited ion signal from the
adducted PC anion upon ionization, which could lead to complications in complex
mixture analysis. The main advantages of the ion/ion chemistry are the high degree of
control over the identities of the reactants via mass-selection prior to reaction, the
avoidance of spectral complexity that can arise in solution phase reaction mixtures, the
avoidance of ion suppression in the ionization step arising from the high salt
concentration in the sample, and ready access to the original [PC+H]+ ions and the
product [PC-CH3]- ion from a single solution and set of ionization conditions. Solution
phase experiments with 18:0/16:0 PC (Figure 6) produced results similar to those
observed with 16:0/18:1 PC. The dissociation behavior of [PC18:0/16:0-CH3]- derived from
the solution phase is also similar to that observed with the ion/ion chemistry.

7.5

Conclusions

Synthetic phosphatidylcholine monocations have been subjected to ion/ion
reactions with doubly deprotonated PDPA.

Collisional activation of the long-lived

complex, comprised of PDPA and PC, generates a demethylated PC anion (i.e., [PCCH3]-), indicating transfer of a proton from the phosphate group and methyl cation from
the quaternary amine group to the carboxylate groups of PDPA. Ion trap CID of [PCCH3]- generates product ions consistent with charged fatty acid chains and neutral losses
of the acyl chains from the PC analyte as free acids and ketenes. Fragmentation spectra
generate structurally informative product ions, which allows for the elucidation of fatty
acid composition (i.e., the number of carbons and degree of unsaturation in each acyl
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chain). The dissociation behavior of demethylated PC anions also exhibits preferential
cleavages at the sn-2 over the sn-1 position as reflected in the relative abundances. The
dissociation behaviors in this study are consistent with previous solution phase
experiments reported in the literature. Solution phase studies demonstrated here, where a
mixture of PC and PDPA are directly ionized via negative mode nESI, show that the
complex that leads to demethylated PC anions can also be formed directly in solution,
although with relatively low abundance. The ion/ion reaction approach is attractive in
that a single set of ionization conditions in one polarity, which can be optimized for
[PC+H]+ formation, can be used to generate two ion-types, the [PC+H]+ and [PC-CH3]ions, that provide complementary information upon CID.
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Scheme 1: The sequence of generating [PC-CH3]- via ion/ion reactions between PDPA
dianions and PC monocations. Top, mass-selected precursor ions; middle, electrostatic
complex generated via a mutual storage ion/ion reaction; bottom, the main products
following collisional activation of the negative complex.
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Figure 7.1: (a) Product ion spectrum following ion/ion reactions between PDPA dianions
and 16:0/18:1 PC monocations, (b) Ion trap CID of the long-lived complex,
[PC16:0/18:1+PDPA-H]-.
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Figure 7.2: (a) Product ion spectrum following ion/ion reactions between PDPA dianions
and 18:1/16:0 PC monocations, (b) Ion trap CID of the long-lived complex,
[PC18:1/16:0+PDPA-H]-.
Figure 7.3: (a) Ion trap CID of [PC16:0/18:1-CH3]-. (b) Ion trap CID of [PC16:0/18:1+H]+. (c)
Relating bond cleavage and product ion type for [PC16:0/18:1-CH3]-.
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Figure 7.4: (a) Ion trap CID of [PC18:1/16:0-CH3]-. (b) Ion trap CID of [PC18:1/16:0+H]+.

178

Figure 7.5: (a) Ionization of PDPA and 16:0/18:1 solution phase mixture via negative
mode nESI (b) Ion trap CID of [PC16:0/18:1-CH3]-.
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Figure 7.6: (a) Ionization of PDPA and PC18:1/16:0 solution phase mixture via negative
mode nESI (b) Ion trap CID of [PC18:1/16:0-CH3]-.
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ABSTRACT: Atmospheric pressure matrix-assisted laser desorption/ionization (AP-MALDI)-derived tryptic peptide ions have
been subjected to ion/ion reactions with doubly deprotonated 4formyl-1,3-benzenedisulfonic acid (FBDSA) in the gas-phase. The
ion/ion reaction produces a negatively charged electrostatic
complex composed of the peptide cation and reagent dianion,
whereupon dehydration of the complex via collision-induced
dissociation (CID) produces a Schiﬀ base product anion.
Collisional activation of modiﬁed lysine-terminated tryptic peptide
anions is consistent with a covalent modiﬁcation of unprotonated primary amines (i.e., N-terminus and ε-NH2 of lysine).
Modiﬁed arginine-terminated tryptic peptides have shown evidence of a covalent modiﬁcation at the N-terminus and a
noncovalent interaction with the arginine residue. The modiﬁed anions yield at least as much sequence information upon CID as
the unmodiﬁed cations for the small tryptic peptides examined here and more sequence information for the large tryptic
peptides. This study represents the ﬁrst demonstration of gas-phase ion/ion reactions involving MALDI-derived ions. In this
case, covalent and electrostatic modiﬁcation charge inversion is shown to enhance MALDI tandem mass spectrometry of tryptic
peptides.

P

Furthermore, MALDI-derived tryptic peptides may generate
limited sequence information due to the basic residue present
at the C-terminus.20−22 Tryptic peptides often generate
fragment ions associated with the C-terminus (e.g., y-ions) as
a result of the C-terminal lysine or arginine sequestering the
excess proton.20 A variety of approaches have been attempted
to improve peptide sequencing in conjunction with MALDI.
For example, condensed-phase peptide modiﬁcation, such as
ﬁxed-charged derivatization of the N-terminus, has been
attempted with mixed success.23,24 A noteworthy approach,
developed by Keough et al., to increase sequence information
from the dissociation of MALDI-derived tryptic peptides
involved conjugating a sulfonic acid group to the N-terminus
via solution phase chemistry.25,26 The objective was to alter
fragmentation pathways by introducing a highly acidic group
into the peptide. Fragmentation was dramatically improved in
derivatized tryptic peptides compared to the underivatized
tryptic peptides. However, the N-terminal position of this
modiﬁcation precluded the presence of N-terminal fragments
due to the anionic sulfonate group.26
We and others have been developing approaches to modify
ions in the gas-phase and within the context of a tandem mass
spectrometry experiment (i.e., modiﬁcation of mass-selected
ions) to expand the capabilities of tandem mass spectrometry

eptide sequencing for identiﬁcation and structural
characterization of proteins is a long-standing activity in
molecular biology research.1 Matrix-assisted laser desorption/
ionization (MALDI)2,3 and electrospray ionization (ESI),4 two
very successful means for the derivation of gas-phase ions from
proteins and peptides, coupled with tandem mass spectrometry,
have become the dominant tools for generating sequence
information from mixtures of peptides.5−8 While there is
signiﬁcant overlap, ESI and MALDI have each found
applications for which they are best suited.9 For example, ESI
has been widely used to interface online liquid separations with
mass spectrometry, whereas MALDI is widely used for
sampling surfaces, as in imaging applications. MALDI has
been adapted to several tandem MS instrument geometries,
e.g., tandem time-of-ﬂight (i.e., TOF/TOF),10 quadrupole/
time-of-ﬂight (i.e., Q/TOF),11 and ion trap12−14 analyzers. The
appeal of ion trap technology is that it permits MSn experiments
to be conducted on MALDI-derived biomolecule ions.15,16
From the standpoint of sequencing, a signiﬁcant diﬀerence
between MALDI and ESI is their propensities for generating
multiply charged ions. Under commonly used conditions,
MALDI generates ions of lower charge than does ESI. In fact,
for peptides, singly charged ions usually dominate. Low-energy
collisional activation of singly protonated tryptic peptides,
however, often does not produce extensive sequence
information.17,18 Dissociation behavior is dominated by lowenergy fragmentation pathways, e.g., cleavage C-terminal to an
aspartic acid residue or N-terminal to a proline residue.19
© 2012 American Chemical Society
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for ion structure characterization using ion/ion reactions.
Ion/ion reactions can be used to decouple the ion type initially
generated by the ionization method from the ion type subjected
to tandem mass spectrometry.28 Structural information derived
from fragmentation is highly dependent upon the nature of the
ion (e.g., positive ion vs negative ion, even-electron ion vs oddelectron, etc.).29 Therefore, ion/ion reactions can expand the
range of ion types that can be subjected to tandem mass
spectrometry relative to the ion types available from the
ionization method. For example, ion/ion reactions have been
used to manipulate peptide ion charge state30,31 and polarity32−34 via the transfer of one or more protons, generate oddelectron ions from even-electron ions via electron transfer,35,36
and insert metal ions into polypeptides.37 Recent studies have
demonstrated the alteration of peptide dissociation behavior via
the gas-phase electrostatic attachment of reagents34,38 and via
the gas-phase covalent modiﬁcation of peptide ions.39−41 All
such examples to date have been restricted to peptide ions
generated via ESI.
In this work, we demonstrate the gas-phase modiﬁcation of
peptide ions generated by atmospheric pressure MALDI (APMALDI)42 using a dual-source interface developed by
Schneider and Covey43 attached to a hybrid triple-quadrupole/linear ion trap tandem mass spectrometer and the
structural characterization of the modiﬁed and unmodiﬁed
versions of the ions via ion trap collision-induced dissociation
(CID). The formation of imine bonds (i.e., Schiﬀ base
formation) using an aldehyde-containing dianion, 4-formyl1,3-benzenedisulfonic acid (FBDSA)44,45 has been demonstrated with peptide ions generated via ESI. Possible sites of
peptide covalent modiﬁcation are the N-terminus and the εNH2 of lysine. Strong noncovalent interactions (i.e., electrostatic modiﬁcation) have also been observed between the
sulfonate groups of FBDSA and peptides containing an arginine
residue and one or more carboxyl groups.38 Covalent bond
cleavage is competitive with disruption of this strong
electrostatic interaction under collisional activation conditions.
In either case (i.e., covalent modiﬁcation or strong electrostatic
binding), the reaction product is a singly charged anion. The
overall approach described here diﬀers from the Keough et al.
approach in that singly charged anions are subjected to CID,
rather than singly charged cations, but is similar in that
sulfonate is introduced into the peptide to alter dissociation
behavior. Ion/ion reactions have been performed on tryptic
peptides of ubiquitin and two synthetic peptides, APPGFSPFR
and GLSDGEWQQVLNVWGK. Collisional activation of
modiﬁed tryptic peptide anions demonstrates modiﬁcation of
the primary amine at the N-terminus and the C-terminal basic
residue. Such modiﬁcations produce both modiﬁed N- and Cterminal fragment ions compared to the solely C-terminal
information observed by Keough. Ion trap CID of the modiﬁed
anions is shown to generate more sequence information than
the unmodiﬁed ion, especially in the form of b-type ions. This
study represents the ﬁrst demonstration of gas-phase
modiﬁcation of MALDI-derived ions via ion/ion reactions.

■

GLSDGEWQQVLNVWGK were purchased from SynPep
(Dublin, CA). Peptides MQIFVK, TITLEVEPSDTIENVK,
EGIPPDQQR, LIFAGK, TLSDYNIQK, and ESTLHLVLR
were generated from a tryptic digestion of ubiquitin.
Methods. The MALDI matrix, CHCA, was prepared in
39.5/59.5/1 (v/v/v) water/acetonitrile/TFA at a concentration
of 10 mg/mL. Peptide analytes were prepared in an ∼100 μM
aqueous solution prior to a 50/50 (v/v) mixture with the
MALDI matrix solution. An amount of 2.0 μL of the matrix/
analyte solution was spotted onto the MALDI stage plate and
allowed to air-dry prior to attachment to the AP-MALDI
source. The anion reagent was composed of a 3.5 mM solution
of 50/50 (v/v) water/acetonitrile for negative microionspray.
Tryptic Digest. The procedure for the tryptic digest of
ubiquitin has been described previously.46 Separation of the
tryptic peptides was performed on a reversed-phase HPLC
(Agilent 1100, Palo Alto, CA) using an Aquapore RP-300 (7
μm pore size, 100 mm × 4.6 mm i.d.) column (Perkin-Elmer,
Wellesley, MA). The gradient for the HPLC separation has
been described previously.46 Following HPLC separation, the
collected fractions were concentrated and reconstituted in 200
μL of water.
Mass Spectrometry. Experiments were performed on a
4000 AB Sciex QTRAP (Concord, ON, Canada), which has
been modiﬁed to perform ion/ion reactions.47 The ion source
is equipped with an AP-MALDI source (MassTech, Columbia,
MD) and with a microionspray emitter (New Objective Inc.,
Waburn, MA) orthogonal to the sample inlet (Figure 1).43,48

Figure 1. Modiﬁed AP-MALDI source, attached to a QTRAP 4000,
capable of multisource injection.

The microionspray emitter, remote to the MS inlet and MALDI
stage plate, allows for the introduction of opposite polarity ions
into the MS. Brieﬂy, the AP-MALDI source has a circular
opening, where a conductive transfer tube penetrates into the
ion source and attaches to the curtain plate. The microionspray
is directed toward the transfer tube, and upon ionization/
nebulization, ions travel into the transfer tube and the ion
source.
The reagent anion, doubly deprotonated FBDSA, was
generated via microionspray at a continuous ﬂow rate of 8.0
μL/min from a silica sprayer (364 μm outer dimension, 48 μm
inner dimension, Polymicro Technologies, Phoenix, AZ). N2
acts as the nebulizing gas, which helps guide the reagent anions
into the ion source. The nebulizing gas was triggered/pulsed via
MS Expo software (AB Sciex, Concord, ON, Canada) during
negative ion injection conditions. Once doubly deprotonated
FBDSA entered the MS, it was transferred to the q2 collision
cell and stored. Tryptic peptides, individually spotted in CHCA,
were ablated via a 337 nm nitrogen laser (AP-MALDI Ion
Source 110, MassTech, Columbia, MD) and transferred to the
q2 collision cell to undergo ion/ion reactions with the reagent

EXPERIMENTAL SECTION

Materials. Triﬂuoroacetic acid (TFA) was purchased from
Pierce (Rockford, IL). Ubiquitin from bovine erythrocytes,
TPCK-treated trypsin from bovine pancreas, α-cyano-4hydroxycinnamic acid (CHCA), FBDSA, and ammonium
bicarbonate were purchased from Sigma-Aldrich (St. Louis,
MO). Synthetic peptides APPGFSPFR and
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lesser abundance. The [M + ⧫]− ions were likely generated by
CID upon transfer from q2 to Q3. Subsequent isolation and
activation of the [M + FBDSA]− ion generates abundant [M +
⧫]− for subsequent interrogation. Contributions from strong
electrostatic binding of the reagent were much more apparent
in the data for the arginine-terminated peptides than for the
lysine-terminated peptides (vide infra). For this reason, results
from lysine- and arginine-terminated peptides are presented
separately.
Lysine-Terminated Tryptic Peptides. Ion trap CID
spectra of protonated TITLEVEPSDTIENVK and the modiﬁed
peptide anion (i.e., [M + H]+ and [M + ⧫]−, respectively) are
compared in Figure 3. Collisional activation of [M + H]+ leads

anions.49,50 In the peptide mixture study, multiple peptides
from the reconstituted solutions were spotted on the MALDI
stage plate with CHCA. All cations produced via MALDI in the
mixture study were transferred to q2 without mass discrimination and reacted with FBDSA dianions. Product ions
generated in q2 were transferred to Q3 for further collisional
activation and subsequent mass analysis.51

■

RESULTS AND DISCUSSION

Ubiquitin was subjected to tryptic digestion and the tryptic
peptides MQIFVK, TITLEVEPSDTIENVK, EGIPPDQQR,
LIFAGK, TLSDYNIQK, and ESTLHLVLR were collected.
The MALDI-derived tryptic peptide ions were subjected to
ion/ion reactions with doubly deprotonated FBDSA. The main
product of the ion/ion reaction is a negatively charged, longlived complex composed of the reagent dianion and tryptic
peptide cation. The complex is formed when a negatively
charged sulfonate interacts strongly with a protonated site on
the peptide. The aldehyde group of the reagent undergoes
nucleophilic attack by a neutral primary amine of the peptide
during collisional activation of the complex leading to the
formation of an imine bond (i.e., Schiﬀ base) and loss of a
water molecule. The Schiﬀ base product anion is represented in
spectra by [M + ⧫]−. The process of forming a Schiﬀ base via
gas-phase ion/ion reactions is depicted in process 1:
[M + H]+ + [FBDSA − 2H]2−
→ [M + FBDSA − H]−
→ [M + ⧫]− + H 2O

(1)

The diamond symbol (⧫) represents the mass addition of the
reagent anion following a water loss. Fragments that are
consistent in mass with those that retain the covalent
modiﬁcation are labeled with the diamond. The negative ion
mode post-ion/ion reaction spectrum (Figure 2a) and positive

Figure 3. Ion trap CID product ion spectra of (a) [M + ⧫]−. (b) [M +
H]+ derived from M = TITLEVEPSDTIENVK.

to 9 of 15 amide bond cleavages, producing 11 fragment ions
(Figure 3b). Fragmentation of the singly protonated peptide
produces limited sequence-informative ions as well as noninformative neutral losses. The product ion spectrum produces
relatively large contributions from the fragment ions y6 and y9.
The fragment ion y6 arises from the well-established C-terminal
cleavage of aspartic acid,52 while the fragment ion y9 originates
from the well-established N-terminal cleavage of the proline
residue.53 Dominance of low-energy fragmentation pathways
has been frequently observed in tandem MS experiments with
MALDI-derived peptide cations.19 When compared to b-ions,
the y-ions clearly dominate the fragmentation spectrum of the
unmodiﬁed cation. Collisional activation of the peptide cation
produced only four b-ions compared to seven y-ions. Limited
N-terminal information (e.g., b-ions) from the collisional
activation of [M + H]+ can be explained by the presence of a
C-terminal basic lysine residue as reported by Biemann.20
Collisional activation of modiﬁed TITLEVEPSDTIENVK
(Figure 3a) produces distinct dissociation behavior compared
to the unmodiﬁed spectrum. In the product ion spectrum, the
most abundant peaks are associated with modiﬁed b- and yions, which are represented as b⧫ or y⧫. The nomenclature of
modiﬁed fragment anions is adapted from the peptide literature
for protonated peptides.54 The b⧫-ions are interpreted to arise
from a covalent modiﬁcation of the N-terminus, while the y⧫ions are interpreted to arise from the covalent modiﬁcation of
the ε-NH2 of lysine. Collisional activation of the modiﬁed
peptide anion produces a higher degree of fragmentation than
the unmodiﬁed peptide cation, where 12 of 15 amide bonds are

Figure 2. (a) Ion/ion product spectrum of peptide cation mixture and
[FBDSA − 2H]2−. (b) Positive ion spectrum of peptide mixture
LIFAGK, EGIPPDQQR, and TLSDYNIQK.

MALDI mass spectrum of a mixture of three tryptic peptides
(viz., LIFAGK, EGIPPDQQR, and TLSDYNIQK) are
compared in Figure 2. Figure 2a was generated by exposing
peptide cations of Figure 2b to a reaction with doubly
deprotonated FBDSA. The ion/ion reaction generated a
product spectrum containing primarily the intact complex
(i.e., [M + FBDSA]−) and signals due to [M + ⧫]− of much
10681
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ions is limited. The modiﬁed peptide anion produces a
signiﬁcant number of b⧫-ions and an even higher number of
y-type ions due to the presence of y1⧫ and y2⧫. With a neardoubled increase of y-and b-type ions (i.e., 13 vs 7 fragment
ions), the modiﬁed peptide ion clearly produced more
sequence information compared to the unmodiﬁed peptide.
The peptides TITLEVEPSDTIENVK and TLSDYNIQK are
illustrative of the synthetic peptide
GLSDGEWQQVLNVWGK. Collisional activation of the
modiﬁed and unmodiﬁed GLSDGEWQQVLNVWGK is
provided in the Supporting Information (Figure S-1). Ion
trap CID of [M + ⧫]− produces a high order of b⧫- and y⧫ions (Supporting Information Figure S-1a), while the
protonated peptide produces limited b- and y-ions (Supporting
Information Figure S-1b). The modiﬁed peptide anion again
produced a higher order of sequence information than the
unmodiﬁed peptide cation. However, the aforementioned
lysine-containing peptides are not necessarily illustrative of
low m/z peptides, such as MQIFVK (Figure 5) and LIFAGK
(Supporting Information Figure S-2).

cleaved, generating a total of 16 fragment ions and a signiﬁcant
increase in N-terminal information. In the spectrum of the
modiﬁed ion, seven b⧫-ions are produced compared to four bions in the spectrum of the unmodiﬁed peptide. We note that
previous studies have clearly shown that [M + ⧫]− ions yield
signiﬁcantly more sequence information upon CID than the
corresponding [M − H]− ions.38,44,45 The incorporation of the
two sulfonate groups into the peptide is expected to have a
signiﬁcant impact on proton mobility within the anion, which
inﬂuences the favored dissociation pathways. This may favor
charge-remote processes,55,56 or it may require the ions to be
elevated to higher energies in order to promote intramolecular
transfer. In any case, the disulfonic acid modiﬁcation to the
peptide has been shown to lead to consistently greater
sequence coverage than singly charged versions of the
unmodiﬁed peptide (i.e., [M + H]+ or [M − H]−).38,44,45
Furthermore, modiﬁcation at the N-terminus gives rise to much
greater contributions from anionic b⧫-ions, which are not
readily observed without the modiﬁcation. Ion trap CID of [M
+ ⧫]− also appears to have less selective cleavage along the
peptide backbone compared to the peptide cation, which has
been observed in previous studies.45
Another ubiquitin tryptic peptide with a C-terminal lysine,
TLSDYNIQK, produced results similar to those noted for the
peptide TITLEVEPSDTIENVK. Ion trap CID of modiﬁed
TLSDYNIQK (i.e., [M + ⧫]−) produced a high degree of
sequence information, where a cleavage at every amide bond is
observed (Figure 4a). The presence of many b⧫- and y⧫-ions

Figure 5. Ion trap CID product ion spectra of (a) [M + ⧫]−. (b) [M +
H]+ derived from M = MQIFVK.

Ion trap CID of modiﬁed MQIFVK (i.e., [M + ⧫]−)
produces mainly y⧫-ions at four of the ﬁve amide bond
cleavages (Figure 5a) and only one ion in the b⧫-ion series
(i.e., the b⧫5-ion), which is distinct from the observation of
many more b⧫-ions from the large modiﬁed peptide ions (i.e.,
TITLEVEPSDTIENVK, TLSDYNIQK, and
GLSDGEWQQVLNVWGK). Ion trap CID of the unmodiﬁed
peptide cation produces many b- and y-ions, which account for
four of the ﬁve amide bond cleavages (Figure 5b). Smaller
peptide ions tend to yield more extensive sequence information
in general.17 While similar amide bonds are cleaved in the
modiﬁed and unmodiﬁed peptide ions, there is a degree of
complementarity from the two peptide ion types. The modiﬁed
anion produces lower m/z y⧫-ions, while the [M + H]+
produces mainly b-ions. Also, the relative contributions of the
fragment ions in the product ion spectra are markedly diﬀerent.
The modiﬁed peptide ion produces a highly abundant y3⧫-ion,
and the peptide cation generates a highly abundant internal
fragment ion, showing the distinct dissociation behavior. The
results from the peptide MQIFVK are illustrative of the peptide
LIFAGK (Supporting Information Figure S-2). Ion trap CID of
[LIFAGK + ⧫]− produces mainly modiﬁed y⧫-ions, which is
consistent with the covalent modiﬁcation of the ε-NH2 of

Figure 4. Ion trap CID product ion spectra of (a) [M + ⧫]−. (b) [M +
H]+ derived from M = TLSDYNIQK.

is consistent with the covalent modiﬁcation of the N-terminus
and ε-NH2 of lysine. The high relative contribution of b4⧫ in
the product ion spectrum is attributed to the labile C-terminal
cleavage of aspartic acid.52 The presence of b1⧫ is particularly
noteworthy because the b1-ion is not typically observed in the
collisional activation of unmodiﬁed protonated and unprotonated peptides.57,58 Ion trap CID of the singly protonated
peptide generates a product ion spectrum with seven of eight
amide bond cleavages (Figure 4b); however, many less
informative fragment ions are also observed in the spectrum
(e.g., internal fragments and neutral losses). The product
spectrum of the unmodiﬁed peptide cation is dominated by the
C-terminal cleavage of aspartic acid, generating the highly
abundant y5-ion. Conversely, the modiﬁed anion appears to
fragment more uniformly. Dissociation of the peptide cation is
dominated by the generation of y-ions, while the presence of b10682
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lysine. Collisional activation of the unmodiﬁed peptide cation
produces a-, b-, and y-ions. Ion trap CID of both the modiﬁed
and unmodiﬁed versions of LIFAGK displays a degree of
complementarity, much like MQIFVK.
Arginine-Terminated Tryptic Peptides. Previous studies
of the ion trap CID of modiﬁed arginine-containing peptides
[i.e., angiotensin II (DRVYIHPF) and ubiquitin tryptic
peptides] demonstrated product ion spectra consistent with
two product populations: Schiﬀ base formation and noncovalent binding of the reagent to the guanidinium side chain
of arginine.39,45 Product ion spectra showed the appearance of
y⧫-ions; however, the only primary amine in the peptide
capable of engaging in Schiﬀ base formation was the Nterminus. The y⧫-ions were determined to arise from [M +
⧫]− ions composed of an electrostatic interaction with the
arginine guanidinium side chain. The water loss leading to the
nominal [M + ⧫]− originated from elsewhere in the peptide
(i.e., it was unrelated to the reagent). The presence of y +
FBDSA ions also provided evidence of an electrostatic rather
than a covalent interaction. Model systems (i.e., YGGFLX
peptides) further demonstrated strong interactions between the
sulfonate groups and peptides containing an arginine residue
and one or more carboxyl groups (e.g., C-terminus) in the gas
phase.38 These noncovalent interactions with FBDSA dianions
are suﬃciently strong that covalent bond cleavage can compete
with reagent detachment upon collisional activation.38,45
Ion trap CID of modiﬁed EGIPPDQQR is displayed in
Figure 6a. Collisional activation of the modiﬁed anion

[M + FBDSA − H − H 2O]

→ M − H 2O + [FBDSA − H]−

(2)
−

The high relative abundances from [FBDSA − H] and y3 +
FBDSA are particularly noteworthy. The signiﬁcantly higher
relative abundance of y3 + FBDSA than [FBDSA − H]−
suggests that the electrostatic interaction can compete with
cleavage of covalent bonds upon collisional activation. Such a
competition gives rise to the y⧫- and y-FBDSA ions.
Collisional activation of the modiﬁed anion produces a
higher order of sequence information than the peptide cation.
The modiﬁed anion produces a mixture of ten y + FBDSA and
y⧫-ions, and when combined, the mixture produces seven of
the eight possible C-terminal amide bond cleavages. The
modiﬁed peptide also produces more N-terminal fragments, i.e.,
b3⧫, b6⧫, and b8⧫, relative to the unmodiﬁed peptide cation.
Collisional activation of the singly protonated EGIPPDQQR
produces limited sequence information in comparison to the
modiﬁed version, as seen previously. The unmodiﬁed cation
produces mainly y-ions, while only a single b-ion was produced.
Dissociation of the peptide cation is dominated by cleavage Cterminal to the acidic residues, i.e., the y3- and y8-ions, as seen
in many MALDI-derived MS/MS experiments. Activation of
the unmodiﬁed peptide cation produces similar y-type ions to
the modiﬁed version, while the modiﬁed anion produces lower
m/z y-type ions that the unmodiﬁed version lacks.
Ion trap CID of the modiﬁed and unmodiﬁed synthetic
tryptic peptide, APPGFSPFR, is illustrated in Figure 7. The

Figure 6. Ion trap CID product ion spectra of (a) [M + ⧫]−. (b) [M +
H]+ derived from M = EGIPPDQQR.

Figure 7. Ion trap CID product ion spectra of (a) [M + ⧫]−. (b) [M +
H]+ derived from M = APPGFSPFR.

generated fragment ions consistent with covalent and electrostatic modiﬁcations. The presence of b⧫-ions is consistent with
the covalent modiﬁcation of the N-terminus, while y⧫ and yFBDSA ions are consistent with an electrostatic attachment to
the peptide (e.g., reagent interaction with arginine and Cterminus). The presence of y⧫-ions can be attributed to the
electrostatic attachment of the FBDSA dianion to the Cterminal arginine and a water loss within the fragment ion (e.g.,
aspartic acid residue). The loss of [FBDSA − H]− also indicates
an electrostatic interaction between the analyte and reagent.
The loss of [FBDSA − H]− generates a neutral dehydrated
peptide due to proton transfer within the complex, as seen in
process 2.

modiﬁed anion produces cleavages at all eight amide bonds,
and the most notable observation in the product ion spectrum
is the generation of a b⧫-ion at each peptide bond (Figure 7a),
including the b1⧫-ion. Collisional activation of [M + ⧫]−
produces a combination of y⧫- and y + FBDSA ions. The
product ion spectrum shows a high contribution from the wellestablished N-terminal cleavage of the proline residue (i.e., b6⧫
− H2O); however, more uniformity of cleavage among amide
bonds is observed compared to the unmodiﬁed cation. While
the ion trap CID of [M + H]+ (Figure 7b) and [M + ⧫]−
produces similar higher m/z y-type product ions, the modiﬁed
anion also produces lower m/z modiﬁed y-ions (i.e., y1 +
FBDSA). The most noteworthy observation of the product ion
spectra is the drastic diﬀerence between the N-terminal
10683
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Notes

fragment ion information. Collisional activation of the peptide
cation produces only three b-ions, while the modiﬁed anion
produces eight b⧫-ions. The presence of the b⧫-ions
signiﬁcantly increases the observed sequence information.
The results of EGIPPDQQR and APPGFSPFR are illustrative
of ubiquitin tryptic peptide ESTLHLVLR (Supporting
Information Figure S-3). Ion trap CID of [ESTLHLVLR +
⧫]− produces a mixture of y⧫- and y + FBDSA ions along with
higher m/z b⧫-ions. The unmodiﬁed peptide cation produces
similar b- and y-type ions; however, the modiﬁed anion
additionally produces lower m/z modiﬁed y-ions, i.e., y1 +
FBDSA.
We note that many of the singly protonated peptides derived
by MALDI and subjected to ion/ion reactions in this work have
also been derived via electrospray and subjected to reactions
with the same reagent.45 Very similar product ion spectra were
derived from the same peptide ions derived by these two
ionization methods. Not surprisingly, the main diﬀerence in the
two approaches was that singly protonated peptides dominated
in all cases in the MALDI experiment, whereas multiply
protonated peptides were the major ions noted for the larger
peptides in the electrospray experiment.
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